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Abstract 
Prostate cancer is the second most common cause of death from cancer in 
men in the UK. Localised disease can be treated with surgery or 
radiotherapy, but metastasis remains a great therapeutic challenge. Cancer 
cell migration involves rearrangements of the actin cytoskeleton, which is 
mediated by its interaction with myosins, a large and diverse family of motor 
proteins involved in many processes crucial for cell migration, such as cell 
adhesion, cell polarity or endocytosis. It is likely that the activity of myosins 
contributes to metastatic spread. 
I investigated the myosin expression profile in prostate cancer cell lines and 
found that Myo1b, Myo9b, Myo10 and Myo18a were expressed at higher 
levels in cells with high metastatic potential. Using an siRNA-based 
approach, knockdown of each myosin resulted in distinct phenotypes. 
Myo10 knockdown drastically decreased filopodia of PC3 cells, Myo18a 
knockdown increased filaments of non-muscle myosin 2A, knockdown of 
Myo1b and Myo9b increased stress fibre formation. Loss of Myo10 affected 
cell migration in 2D. In all cases, cell spread area was increased and 3D 
migration potential was decreased for Myo1b, Myo10 and Myo18a. Myo1b, 
Myo10 and Myo18a were also expressed in benign prostatic hyperplasia 
although knockdown of these myosins in benign tissue did not have very 
clear effects. Glioblastoma cells expressed high levels of Myo10 and 
showed decreased protrusions after Myo10 knockdown. 
Taken together, myosins act as molecular motors but also directly influence 
actin organisation and cell morphology and migration, which can contribute 
to the metastatic phenotype of cancer cells. 
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Chapter 1 
Introduction 
 
1.1  Cancer characterisation 
Cancer is not just a single disease, but a group of diseases characterised by 
the uncontrolled growth and spread of abnormal cells. The complexity of this 
group of diseases can be described through the underlying principles, also 
known as the hallmarks of cancer (Hanahan and Weinberg, 2000): 
- Self-sufficiency in growth signals 
- Evading apoptosis 
- Insensitivity to anti-growth signals 
- Tissue invasion & metastasis 
- Limitless replicative potential 
- Sustained angiogenesis 
These have been complemented by the “next generation” hallmarks 
(Hanahan and Weinberg, 2011): 
- Avoiding immune destruction 
- Deregulating cellular energetics 
- Genome instability and mutation 
- Tumour-promoting inflammation 
Even though the field of cancer research has grown extensively, there are 
still many questions that remain unanswered. In my study, I have focused on 
the metastasis of prostate cancer, trying to examine the mechanisms 
underlying this process. 
 
1.1.1 Prostate cancer statistics 
Almost 7.5 million men worldwide were diagnosed with cancer in 2012 
(Torre et al., 2015). Out of these, prostate cancer accounted for 1.1 million 
cases, or 15%, making it the second most common cancer in men 
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worldwide, after lung cancer (Torre et al., 2015). The incidence rates vary up 
to 100-fold across the world, remaining very low in most of Asia and Africa.  
The rates are highest in Australia, North America and Western Europe, 
where almost 70% of all cases occurred (759 000 in 2012) (Figure 1.1) 
(Torre et al., 2015). In the UK, prostate cancer accounts for 25% of male 
cases of cancer and is the most common cancer type (Cancer Research UK 
website) (more than 41 000 out of 167 000 in 2011). Prostate cancer is the 
fifth leading cause of death from cancer in men worldwide (estimated 307 
000 deaths in 2012) (Torre et al., 2015) and second in the UK (around  
10 800 deaths in 2012, Cancer Research UK website). Mortality rates 
worldwide show less variation than incidence, with the number of deaths 
generally high in predominantly black populations (Caribbean and sub-
Saharan Africa, among others), very low in Asia and intermediate in the 
Americas and Oceania (Jemal et al., 2011).  
Much of the variation in incidence reflects differences in cancer detection. 
The high incidence rates reported especially in developed countries largely 
result from the widely used prostate specific antigen (PSA) testing that 
detects clinically important tumours but also slow-growing, benign cancers 
that might otherwise have escaped diagnosis, which in turn creates the 
potential for overdiagnosis (Etzioni et al., 2002). Screening for prostate 
cancer using PSA testing remains a controversial subject, since multiple 
studies into using the test have had conflicting results and there is currently 
no clear evidence that PSA testing reduces prostate cancer mortality (Etzioni 
et al., 2002). By the age of 80, most men will have some cancerous cells in 
their prostate, but only 1 in 25 of them will die from prostate cancer (Cancer 
Research UK website). On the other hand, some prostate cancers will grow 
quickly and spread to other parts of the body within a few years. For 
screening to be most helpful, it should only pick up prostate cancers that are 
faster growing and likely to be a threat to health, but there is currently no test 
that can reliably do this. 
Older age, race (black), and family history remain the only well-established 
risk factors for prostate cancer (Jemal et al., 2011). Currently no preventable 
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risk factors for prostate cancer have been established (Jemal et al., 2011), 
although some studies suggest that, similarly to other cancer types, lifestyle 
could be important in prostate cancer prevention (Holly et al., 2013). The 
reason for the high prostate cancer risk among some populations of African 
descent is still poorly understood, though it may in part reflect differences in 
genetic susceptibility (Zeigler-Johnson et al., 2008).  
 
1.1.2 Prostate cancer stages and therapies 
The majority of prostate tumours are adenocarcinomas, which means they 
originate from the glandular epithelium in the prostate, mostly in the 
peripheral zone (Long et al., 2005). Prostate cancer tends to progress slowly 
(i.e. 83.8% of men experience a 10-year survival in England and Wales 
following diagnosis). Many cancers stay benign, but a fraction become 
metastatic at various stages and an absolute prediction of when a localised 
cancer will spread is not possible. Nonetheless, several factors are used to 
decide if cancer is low or high risk and therefore choose the treatment 
necessary (Cancer Research UK website). These include monitoring the 
levels of PSA in the blood, generating a Gleason score resulting from 
histological analysis of biopsies; the score is low if cells resemble normal 
prostate tissue (low grade cancer) and high if cells appear de-differentiated 
or invading the surrounding tissue (high grade/high risk cancer), and TNM 
staging, which assesses the size of the tumour (T), the spread to lymph 
nodes (N) and secondary cases (Metastases, M). 
Currently used standard of care options for prostate cancer depend on the 
stage at which the disease is detected. Different treatments are optimised for 
the best results at different stages and can be combined to obtain higher 
efficiency. The most popular therapy strategies for localised prostate cancer 
include: surgery (e.g. radical prostatectomy), radiotherapy (external beam 
radiation therapy or radioactive seed implants in the prostate) and/or active 
surveillance or watchful waiting.  
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Figure 1.1 Prostate cancer worldwide. A. Most common cancer sites 
worldwide in males, 2012. Prostate cancer marked by purple colour.  
B. International variation in prostate cancer incidence rates, 2012 (per 
100,000, age standardized to the World Standard Population). (Torre et al., 
2015)   
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The prostate as well as prostate cancer depends on testosterone, the most 
well-known androgen, for growth. This means that hormone therapy can also 
be used to lower the levels of testosterone, especially if the tumour has 
started invading neighbouring tissues or spreading to other organs. 
Androgen deprivation therapy is one of the most effective forms of treatment 
for patients with disseminated disease (Augello et al., 2014). However, 
progression of prostate cancer is also connected with a loss of response to 
androgen levels (Sharifi et al., 2010). As a consequence, hormone therapy is 
therefore efficient for some time, but after 2-3 years cancer can progress into 
castration-resistant prostate cancer (CRPC). At this stage chemotherapy is 
used, such as treatment with taxane, although current methods only extend 
patients life by up to several months (D'Amico et al., 1998; Sharifi et al., 
2010; Wolff and Mason, 2012). Prostate cancer very often metastasises to 
the bone, and in addition to chemotherapy, a new radioactive reagent has 
recently been approved to treat CRPC of the bone (Bishr and Saad, 2013; 
Parker et al., 2013). 
Apart from the risk associated with the tumour itself, the choice of treatment 
depends on the age of the patient and his health (Hoskin et al., 2013). 
However, despite all the strategies available, both for early detection and 
treatment of localised prostate cancer, a number of patients will develop the 
disseminated metastatic disease, which remains largely untreatable 
(Albertsen et al., 2005; Wolff and Mason, 2012). This brings the need to 
study the mechanisms responsible for prostate cancer progression and 
metastasis. Understanding the biology of prostate tumours may help focus 
new research and the development of effective therapies to combat 
metastatic disease, and diagnostic factors to more accurately predict the risk 
of its potential progression. 
 
1.1.3 Prostate cancer models 
Despite considerable scientific effort, relatively little is known about the 
biological events causing the initiation and progression of prostate cancer. 
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To better understand the cellular and molecular events underlying the 
disease, many models of prostate cancer have been developed. These 
include animal models such as genetically engineered mice, xenografts and 
rat models, and transformed human prostate epithelial cell lines, such as 
LNCaP, DU145, PC3 and others.  
Different models have inherent advantages and disadvantages, for example 
animal models can include the important interaction with the tumour 
microenvironment, stroma, immune cells, blood vessels etc., but prostate 
disease can be different in animals than in humans (Grabowska et al., 
2014). Mice are quite resistant to developing invasive prostate cancer, and 
once they have invasive disease, it often does not resemble the human 
disease (reviewed in (Grabowska et al., 2014)). On the other hand, tissue 
culture models, although simplistic, represent human cells and are useful in 
understanding basic biology of prostate cancer or can serve as a good 
means for an initial screen.  
Amongst the most popular cell lines developed and described in prostate 
cancer are the well-characterised “classic” cell lines: LNCaP, DU145 and 
PC3, which were amongst the first to be established. The three cell lines are 
derived from metastatic prostate cancer and have quite different properties 
(Table 1.1). As a model representing benign-like prostate tissue, Benign 
Prostatic Hyperplasia cell line (BPH-1) is also described in the table and will 
be used in this study. 
 
  
 7 
 
Table 1.1  Prostate disorders and prostate cancer cell lines 
 BPH-1 LNCaP DU145 PC3 
Origin 
Benign 
prostate 
hyperplasia 
Metastasis 
from supra-
clavicular 
lymph node 
Metastasis 
from the 
brain 
Metastasis 
from bone 
(Gleason 
grade IV) 
Response to 
androgen 
Androgen-
dependent 
Androgen-
dependent 
Androgen-
independent 
Androgen-
independent 
Invasive-
ness 
None Low Medium High 
Ploidy 
Aneuploid (76 
chromosomes) 
Hypotetraploid Hypotriploid Near-triploid 
p53 status 
wt 
(dysfunctional) 
wt mutant null 
Reference: 
(Hayward et 
al., 1995) 
(Horoszewicz 
et al., 1983) 
(Stone et al., 
1978) 
(Kaighn et al., 
1981) 
 
BPH-1 (Benign Prostatic Hyperplasia) is an epithelial cell line that has been 
established from hyperplastic human prostate tissue. Benign prostatic 
hyperplasia is a prostate disorder that is not considered to act as a precursor 
to prostate cancer (in contrast to prostatic intraepithelial neoplasia, PIN) 
(Orsted and Bojesen, 2013), partly because it appears in a different region of 
the prostate to prostate cancer and PIN. In contrast, the likelihood of 
prostate cancer development in patients exhibiting PIN increases with the 
detection of elevated serum levels of the PSA (Zlotta and Schulman, 1999). 
The BPH-1 cell line has been immortalised but not transformed, and it 
retains some important characteristics of benign prostatic epithelium in vivo. 
In comparison to DU145 and PC3, the LNCaP cell line represents an ‘early’ 
stage of prostate cancer metastasis, because it is still androgen-sensitive 
and has low invasive potential (Horoszewicz et al., 1983). The invasive or 
metastatic potential can be measured by the cell line ability to migrate 
through trans-wells and into matrices, or their ability to form tumours 
(metastases) when injected into nude mice. PC3 cell line is the most 
malignant, highly proliferative and invasive cells (prostate cancer grade IV) 
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(Kaighn et al., 1981). PC3 represent a more advanced/ aggressive phase of 
cancer cell development and possess characteristics of highly malignant 
neoplasm, 100% cells are aneuploid, and this cell line lacks the wild-type 
p53 protein, a tumour suppressor. The PI 3-Kinase/Akt pathway, which is 
one of the major intracellular pathways responsible for promoting cell 
survival, is constantly active in PC3 cells (Goc et al., 2011). 
1.2 Cell migration 
1.2.1 Cytoskeleton 
The cytoskeleton is a highly dynamic, interconnected network that provides 
support, structure and organisation to cells. The main components of 
cytoskeleton include actin filaments and microtubules, which serve as tracks 
for intercellular transport, and intermediate filaments (Hartman and Spudich, 
2012). Both actin filaments and microtubules have a polarity, which means 
that they each have two structurally and functionally distinct ends. In actin 
filaments, one end is known as the plus (or barbed) end as it is the faster 
growing end. The other is known as the minus (or pointed) end (reviewed in 
(Akhmanova and Hammer, 2010)). The cytoskeleton is vital in many aspects 
of cell migration. Both through actin polymerisation and actomyosin 
contractility, the cytoskeleton provides the main driving force for cell motility 
and is involved in establishment and maintenance of cell adhesion (Ridley, 
2011). Cytoplasmic domains of transmembrane cell adhesion receptors 
(integrins in the case of cell-extracellular matrix contacts and cadherins in 
the case of cell-cell contacts) interact with actin binding proteins that link 
them to actin filaments (Krendel and Mooseker, 2005). Although highly 
organized, the cytoskeleton changes upon cues from a wide variety of 
sources, such as entry into mitosis or in response to external signals. The 
cytoskeleton interacts with dozens of associated motor proteins and other 
accessory proteins, which can mediate many such changes (Goode et al., 
2000). 
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1.2.2 Cell motility in metastasis 
The ability to invade other tissues and create metastases is considered one 
of the hallmarks of cancer (Hanahan and Weinberg, 2000). Cancer cells 
become able to change position within the tissues and to enter the lymphatic 
and blood vessels for dissemination into the circulation, and then undergo 
metastatic growth in distant organs (Friedl and Wolf, 2003). To spread within 
the tissues, tumour cells use migration mechanisms that are similar, if not 
identical, to those that occur in normal, non-neoplastic cells during 
physiological processes such as embryonic morphogenesis, wound healing 
and immune-cell trafficking (Friedl and Wolf, 2003). Invasiveness and 
metastasis are very complex processes, and an important field of study, 
since metastasis is the cause of 90% of deaths from solid tumours (Gupta 
and Massague, 2006).  
For the cells to become metastatic, they must overcome numerous 
obstacles barring metastasis, multiple intrinsic mechanisms in the cell, as 
well as extrinsic barriers (Fidler, 2003). Factors in the tumour 
microenvironment that limit its progression include extracellular matrix 
components, basement membranes, reactive oxygen species, the limited 
availability of nutrients and oxygen and attack by the immune system, and 
can be classified as chemical, physical and biological in nature (Gupta and 
Massague, 2006). This means that the cell must meet certain requirements, 
which are reflected in several steps that create the biological cascade of 
metastasis (Gupta and Massague, 2006), summarised in Figure 2. These 
include the growth of the primary tumour (proliferation and angiogenesis), 
followed by a loss of cellular adhesion (detachment from the primary 
tumour), an increased motility and invasiveness, and then entry and survival 
in the circulation (in blood or lymphatic vessels). The cells can then exit into 
new tissue and start to colonise a distant site (survival in a new 
microenvironment). However, growth of the primary tumour is not a 
necessary step before metastasis, as micrometastases can be found even in 
seemingly small cancers (Mitas et al., 2001).  
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Figure 1.2 Main steps in the formation of metastasis. a) Cellular 
transformation and tumour growth. b) Vascularisation. c) Local invasion of 
the stroma by some cells. d) Detachment of some cells and entering the 
blood or lymphatic vessels. The cells can be trapped in the capillary beds of 
distant organs. e) Extravasation or leaving the bloodstream/lymphatic 
vessels. f) Proliferation within the new organ completes the metastatic 
process. To continue growing, the micrometastasis must develop a vascular 
network and evade destruction by host defences. Adapted by permission 
from Macmillan Publishers Ltd: Nature Reviews. Cancer (Fidler, 2003), 
copyright (2003) 
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The described process is broadly regulated by a developmental regulatory 
programme referred to as the ‘epithelial-mesenchymal transition’ (EMT), 
which has become implicated as a means by which transformed epithelial 
cells can acquire the abilities to invade, to resist apoptosis, and to 
disseminate. It is a multistep process where epithelial cells lose their cell-cell 
and cell-substratum adhesions and acquire properties required for 
independent cell migration (Polyak and Weinberg, 2009).   
A molecular depiction of cell migration in in vitro models involves a 
continuous cycle of interdependent events: dynamic cytoskeletal changes, 
cell-matrix interactions, localised proteolysis, actin-myosin contractions and 
focal contact disassembly (reviewed in (Fidler, 2003; Friedl and Wolf, 2003; 
Gupta and Massague, 2006)). First, the moving cell becomes polarised and 
elongated. It can form filopodia, thin actin-rich protrusions which can probe 
the environment for cues (Heckman and Plummer, 2013). A pseudopod is 
formed via extension of the cell’s leading edge. Then the lamellipodium 
elongates, a process that is driven by actin assembly into filaments, which 
connect to adaptor proteins and push the cell membrane in an outward 
direction. The pseudopod/lamellipodium attaches to the ECM (extracellular 
matrix) substrate and interacts with it via receptors from the integrin family, 
which create so called focal contacts. Surface proteases, such as matrix 
metalloproteinases (MMPs) are employed to cleave elements of the ECM, 
including collagen, laminins or fibronectins, and make space for the cell to 
move. Subsequently, regions of the entire cell body contract, generating 
force that leads to the gradual forward movement of the cell body and its 
trailing edge. This happens as a result of the contractile interaction between 
non-muscle myosin 2 and actin (actomyosin). Finally, at the rear edge of the 
cell, the tail detaches, disassembling the focal contacts, and then recycles all 
the molecules. Unlike physiological processes of cell invasion, the migration 
of tumour cells seems to be activated by a dominance of promigratory 
events in the absence of counteracting stop signals. This imbalance of 
signals allows cancer cells to become continuously migratory and invasive, 
leading to tumour expansion across tissue boundaries, followed by 
metastasis. 
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Cancer cells exhibit various types of cell migration, as individual cells or in 
solid cell groups, strands or clusters in ‘collective cell migration’ (Friedl and 
Wolf, 2003). Individual cells or leading cells in collective migration can use 
mesenchymal cell migration which depends on the cell’s adhesion to 
extracellular matrix (ECM) (Kawauchi, 2012). Individual cells migrating in 
vivo can also have an amoeboid form of cell migration that involves low 
affinity substrate binding and is driven by acto-myosin protrusive forces 
(Friedl and Wolf, 2003; Kawauchi, 2012). 
 
1.2.3 Filopodia and other protrusions 
Migrating cells can exhibit different types of protrusions, including 
invadopodia, which contain proteases, podosomes, and filopodia (Heckman 
and Plummer, 2013). Filopodia are thin, finger-like protrusions that contain 
tightly packed parallel actin filaments and sense the microenvironment 
around the cell (reviewed in (Jacquemet et al., 2015)). The actin filaments 
are tightly packed into bundles by proteins such as fascin, and one of the 
myosins, Myo10, is known to transport various proteins, including 
transmembrane receptors, along actin filaments to the tips of filopodia 
(Figure 1.3). Tips of filopodia contain cell-cell and cell-ECM adhesion 
receptors, as well as cytokine receptors. By transporting integrins, a key 
family of adhesion receptors, filopodia play a central role in modulating cell 
adhesion (Albuschies and Vogel, 2013). Finally, filopodia and filopodial 
proteins make a critical contribution to cancer metastasis and therefore 
constitute attractive therapeutic targets to block cancer dissemination. Thus, 
an important focus for the future will be to identify compounds that inhibit 
filopodia formation and to assess their efficiency to block metastases both in 
vitro and in vivo.  
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 Figure 1.3 Schematic representation of a filopodium during cell 
migration on a planar substrate. Filopodia are in contact with the ECM. 
Filopodia extension is driven by actin polymerisation, mediated by proteins 
such as formins and regulated by actin capping proteins, actin regulators 
such as Ena/VASP (enabled/vasodilator-stimulated phosphoprotein), which 
promote actin filament elongation, and I-Bar proteins like insulin-receptor 
substrate p53 (IRSp53), which deform the plasma membrane (revised in 
(Arjonen et al., 2011)). Source: (Jacquemet et al., 2015). 
  
 14 
 
1.3 Myosin superfamily 
1.3.1 Myosins: structure and function 
Myosins are a large family of motor proteins that are able to move along 
actin tracks, powered by adenosine triphosphate (ATP) hydrolysis (reviewed 
in (Berg et al., 2001; Coluccio, 2008). Next to microtubule-based kinesins 
and dyneins, myosins are the only motor proteins linked to actin, and they 
predominantly move to the barbed end of the actin filament. The only 
exception to date is the pointed end-directed motor myosin 6 (Myo6) (Buss 
and Kendrick-Jones, 2011). The myosin superfamily contains more than 20 
distinct classes. In humans, as many as 40 genes for various myosins are 
expressed, which can be divided into 12 classes (Figure 1.4) (Foth et al., 
2006; Peckham and Knight, 2009). Muscle myosins that build the thick 
filaments are the most well-known, but myosins are quite abundant: with 
each cell expressing up to ~20 different non-muscle myosin isoforms, 
depending on the cellular function (Berg et al., 2001). 
The myosin protein family is diverse but all myosins share a similar body 
plan, which consists of 3 domains (e.g. non-muscle myosin 2 in Figure 1.5) 
(Berg et al., 2001; Coluccio, 2008): 
a) Motor domain (‘head’) at the N-terminus, which is conserved among 
isoforms and contains actin- and nucleotide-binding sites 
b) Lever domain (‘neck’), which transmits the force and can be stabilised 
by binding of calmodulin or calmodulin-like regulatory proteins / light chains 
c) C-terminal domain (‘tail’), which is highly diverse among different 
myosin classes and is responsible for cargo binding, thus dictating the 
function of each myosin (Foth et al., 2006)  
Myosins from class 2, class 5 and class 18 can form dimers (reviewed in 
(Allsop and Peckham, 2011)). The remaining myosins are monomeric, which 
does not rule out the possibility that they could become dimerised in cells via 
adaptors. But at least as isolated molecules, these myosins should be 
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considered monomeric, which will have implications for their function and 
regulation (Peckham and Knight, 2009). 
 
 
Figure 1.4 The myosin family tree in humans, generated using multiple 
sequence alignment of the motor domain sequences. The 39 genes 
encoding myosins are organised into 12 classes. Myosins have a variety of 
N-terminal extensions to their motor domains and diverse domains in their 
tail, depending on their function (Source: Peckham and Knight, 2009). 
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1.3.2 Conventional myosin: class 2  
Class 2 skeletal muscle myosin, which plays a role in muscle contraction,  
was the first one to be studied biochemically (Coluccio, 2008). A myosin 2 
molecule is a hexamer composed of two heavy chains and four light chains 
(Figure 1.5) (Bresnick, 1999). Muscle myosin dimers can be further 
assembled into thick filaments that promote the contraction of muscle fibres. 
In skeletal and cardiac muscle, the myosins assemble into bipolar filaments 
that contain 294 myosin molecules (reviewed in (Craig and Woodhead, 
2006)). In smooth muscle, the myosins form side polar filaments that do not 
have a fixed number of myosin molecules (Murphy et al., 1997). Class 2 also 
includes non-muscle myosins, which form short bipolar filaments that contain 
14-20 molecules (Billington et al., 2013). Class 2 myosins are also abundant 
in non-muscle cells, including non-muscle myosins 2a, 2b and 2c in humans 
(NM2A, NM2B and NM2C). Non-muscle myosin 2s are involved in important 
cellular functions, such as cytokinesis, karyokinesis, cell migration, cell 
polarity during migration and morphological changes (Saha et al., 2011). 
Class 2 myosins are known as conventional myosins, while the remaining 
myosins are referred to as unconventional. 
 
 
Figure 1.5 Schematic diagram of non-muscle myosin 2 (NM2). Dimer of 
heavy chains includes: motor and lever domain to the left (light grey) and tail 
domain (two tail domains forming a coiled coil and a C-terminal non-helical 
part of the tail at the end (light grey)). Two essential light chains (black) and 
two regulatory light chains (dark grey) bound to the neck region. Source: 
(Bresnick, 1999) Copyright © 2013 Landes Bioscience  
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1.3.3 ATPase activity 
Binding of myosin to filamentous actin (F-actin) and its conformational 
changes are regulated by hydrolysis of ATP by the actin-activated Mg2+ 
ATPase in the motor domain (ATPase cycle), and subsequent release of 
products (ADP, Pi) (De La Cruz and Ostap, 2004). Briefly, in resting muscle, 
the myosin crossbridges contain ADP.Pi in their nucleotide binding pockets 
(the products of ATP hydrolysis). When the muscle is activated, myosin is 
then able to bind to actin in the thin filaments. Actin catalyses the release of 
phosphate (Pi) from the nucleotide binding pocket (active site), eliciting a 
conformational change in the motor domain which results in the ‘power 
stroke’ and as a result the motor also binds to actin more tightly. ADP is then 
released from the active site and ATP binds, and releases the motor domain 
from actin.  ATP is then hydrolysed in the detached heads, and the cycle can 
continue. The small change in conformation in the motor domain resulting 
from the release of phosphate is amplified by the lever, to generate the 
‘power stroke’.  
This cycle is common for all myosins, but the binding affinities and rate 
constants can be different, properties of each myosin being adapted for their 
cellular function (Allsop and Peckham, 2011; Berg et al., 2001; Hartman and 
Spudich, 2012). The proportion of time that myosin molecule spends 
strongly attached to actin over the entire ATPase cycle is called the duty 
ratio. The duty ratio varies among myosins, with skeletal myosins having a 
low duty ratio, and myosin 5 (Myo5) having one of the highest (De La Cruz 
and Ostap, 2004). The length of the lever arm is different among the classes 
of myosin motors, which results in different ‘step’ sizes (Hartman and 
Spudich, 2012). With each cycle of ATP hydrolysis, myosins take one step. 
Directed motion also depends on the lever arm, the long lever arm of Myo5 
enables a large step of ~20nm, while the shorter lever arm of myosin 2 
results in a shorter step of ~5-10nm.  
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1.3.4 Myosin regulation 
Smooth muscle and non-muscle myosin 2 dimers bind essential light chains 
(ELC) that stabilise the neck domain and regulatory light chains (RLC) that 
stabilise the neck and regulate motor activity (Figure 1.5) (Trybus, 1994). 
Myosin 2 is regulated by phosphorylation of RLC, and in a fully 
dephosphorylated state it adopts a compact, folded structure, where the tail 
interacts with the motor domain (Ankrett et al., 1991). RLC is phosphorylated 
on different residues by several kinases, such as myosin light chain kinase 
(MLCK) or protein kinase C (PKC), suggesting that myosin 2 is subject of 
regulation by various signal transduction pathways (Beach et al., 2011; 
Ikebe and Hartshorne, 1985). Phosphorylation at Serine 19 by MLCK causes 
the myosin to change conformation, increases the actin-activated ATPase 
activity of the motor and promotes myosin 2 filament assembly (Craig et al., 
1983; Dulyaninova and Bresnick, 2013). Several other proteins have been 
reported to regulate NM2 filament assembly, promoting the depolymerisation 
of myosin filaments. These include lethal giant larvae (Lvl) (Vasioukhin, 
2006), MTS1 (S100A4) (Kriajevska et al., 1994) and S100P (Du et al., 2012) 
(reviewed in (Dulyaninova and Bresnick, 2013)).  
Multiple regulatory mechanisms are known for unconventional myosins, 
including cargo binding, binding of calmodulin and calmodulin-like proteins 
(Akhmanova and Hammer, 2010). Similarly to myosin 2, myosins class 5 
and 7 can also form compact molecules that have a very low ATPase activity 
(Umeki et al., 2011; Wang et al., 2008). Myo6 can be regulated by calcium 
binding via calmodulin, which affects its motor activity, or phosphorylation 
which correlates with its translocation in the cell (reviewed in (Buss and 
Kendrick-Jones, 2008)). The function of Myo10 is promoted by DCC 
(Deleted in Colon Cancer) and suppressed by neogenin, showing a 
differential balance through the function of different regulators (Liu et al., 
2012). Two myosin-specific chaperones are also known in mammals, a 
“general cell” Unc45a and muscle-specific isoform, Unc45b (Price et al., 
2002). 
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1.3.5 Myosins in a migrating cell 
Myosins are abundant, with most cells expressing at least 20 different types 
of myosin which include representatives of at least six different classes of 
the myosin superfamily, including several myosin 1 isoforms, non-muscle 
myosin 2 (NM2) isoforms, and myosins 5, 6, 9 and 10 (reviewed in (Allsop 
and Peckham, 2011). Myosin isoforms have different mechanochemical 
properties, such as the duty ratio or processivity (reviewed in (Ouderkirk and 
Krendel, 2014)). For example, myosins with low duty ratio may function in 
rapid contractile events or serve as dynamic, short-lived tethers between 
actin ﬁlaments and the cargo, while isoforms with high duty ratio are suited 
to generating sustained tension. This diversity allows myosins to contribute 
to many processes important for cell motility, including cell migration and 
invasion through the extracellular matrix, regulation of protein and organelle 
localization, cell shape changes, and cell signalling.  
Many myosins have multiple or partly overlapping functions which include 
roles in cell adhesion and intracellular motility, including cytoskeleton 
dynamics, endocytosis, exocytosis and secretory pathways (Allsop and 
Peckham, 2011). Myosins localise to a number of intracellular compartments 
and participate in many trafficking and anchoring events (Hartman Spudich 
2012). These functions are often class-dependent and some of them are 
summarised in Figure 1.6. Class 1 myosins contain in their C-terminal tail 
membrane-binding and protein interaction domains. This allows them a 
simultaneous binding to phosphatidyl inositol phospholipids (PIPs) and 
vesicles and/or in the plasma membrane and other proteins necessary for 
active membrane deformation or intracellular vesicle trafficking, as well as 
cytoplasmic domains of transmembrane receptors (McConnell and Tyska, 
2010; Wenzel et al., 2015). Class 5 myosins are well known to be involved in 
trafficking a variety of cargo in cells (Wang et al., 2008). Some myosins have 
a more specialised role, such as myosin 19 (Myo19), shown to traffic 
mitochondria in cells (Quintero et al., 2009) or a role in actin-based 
projections, such as myosin 10 (Myo10) present in filopodia (Liu et al., 
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2012). Myo6 is associated with endocytic vesicles and endosomes (Buss 
and Kendrick-Jones, 2011). During cell migration, non-muscle myosin 2a 
(NM2A) is dynamic and responsible for the movement forward; by contrast, 
NM2B incorporates into preformed F-actin bundles and has a role in defining 
the rear of the migrating cell and tail retraction (Dahan et al., 2012; Swailes 
et al., 2006). The different location and expression levels of different non-
muscle myosins are likely to play a major role in cell shape and cell-cell 
adhesion (Swailes et al., 2006). Myosin 2-dependent contractility may play 
an important role in coordination of cell migration and directional motility by 
preventing formation of lateral pseudopods and limiting 
pseudopodial/lamellipodial protrusion to the leading edge of the cell (Krendel 
and Mooseker, 2005). 
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Figure 1.6 Myosins in a migrating cell. Various myosins have different 
functions (detailed description and references in the main text body). Class 1 
myosins seen at the membrane; Myosin 2 responsible for contractility and 
tail retraction, among others; according to their functions, Myo6 involved in 
endocytosis, Myo10 at the filopodia; Myo18a in the lamellipodium. (From  
M. Peckham, with permission). Yellow boxes represent respective labelled 
processes (from left to right: tail retraction, nuclear function, organelle 
motility, cell-matrix adhesion, endocytosis, cortical and lamellipodial 
functions, exocytosis, phagocytosis/micropinocytosis, filopodium). 
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1.4 Objectives of this study 
Despite multiple approaches available and considerate research effort, 
prostate cancer at metastatic stage remains largely untreatable, bringing the 
need to study the mechanisms responsible for prostate cancer progression 
and metastasis. The main aim of this project is thus to establish if myosins 
contribute to metastasis of prostate cancer. An initial screen identified the 
myosins present in prostate cancer cell lines and tissue, including isoforms 
upregulated in metastatic prostate cancer. This was followed by an analysis 
of chosen myosins on functional level using siRNA technique, to investigate 
their effect on morphology and migration of prostate cancer. Finally, I also 
looked at myosins in other types of tissue, including benign prostate cells 
and another type of cancer (glioblastoma). 
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Chapter 2 
Materials and methods 
 
2.1 Cell lines and cell culture 
2.1.1 Prostate cancer and prostatic hyperplasia cell lines 
LNCaP, DU145 and PC3 cells were obtained from ATCC. The BPH-1 cell 
line was a gift from Dr Sivaprasadarao, University of Leeds. Characteristics 
of the cell lines are described in more detail in Section 1.1.3. The cells were 
grown in RPMI-1640 with GlutaMAX™ (Gibco® Life Technologies™) 
supplemented with 10% heat inactivated FBS (foetal bovine serum) and 
antibiotics (penicillin (100 units/ml) and streptomycin (100 g/ml), Gibco® 
Life Technologies™).  
 
2.1.2 Matched pair of patient cells 
1535 NP (Normal Prostate) and 1535 CT (Cancerous Tissue) cells, originally 
derived from primary adenocarcinomas from the prostate (Bright et al., 
1997), were a gift from Suzanne Topalian, John Hopkins University School 
of Medicine, USA. They were grown in Keratinocyte medium (Gibco® Life 
Technologies™) supplemented with 10% heat inactivated FBS, 1% L-
glutamate, antibiotics (penicillin (100 units/ml) and streptomycin (100 g/ml), 
Gibco® Life Technologies™), bovine pituitary extract (50 g/ml) and 
epidermal growth factor (5 ng/ml). 
 
2.1.3  Glioblastoma cell culture 
p53lox/lox /PTENlox/lox or PTENlox/lox glioma cell line (referred to also as  
glioma p53-/-PTEN-/- and PTEN-/- in the text) derived from a mouse model 
was provided to us as a kind gift from Dr Stephen Rosenfeld, Department of 
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Cancer Biology, Cleveland Clinic Foundation (unpublished). The cells were 
grown in BBFP medium (2 units Basal medium, 1 unit B104-conditioned 
medium (see Section 5.2.2 below), supplemented with 10 ng/ml FGF and 10 
ng/ml PDGF). Basal medium comprises: DMEM w/ 4.5 g Glucose, 
w/glutamine, w/Pyruvate (Gibco® Life Technologies™) with 0.1% (v/v) T3 
(3,3′,5-Triiodo-L-thyronine, 20 μg/ml stock solution in DMEM), 1% (v/v) N-2 
Supplement (Gibco® Life Technologies™), 1% (v/v) PSA (Penicillin, 
Streptomycin, Ampicillin; Invitrogen) and 0.5% (v/v) FBS.  Cells were grown 
at 37°C with 5% CO2 and passaged when reached about 75% confluence. 
Passaging, harvesting and fixing of the cells was performed as previously 
described for other cell types (see Sections 2.1 and 2.4). The glioblastoma 
cells required to grow on surfaces coated with Poly-L-Lysine (as described 
below in Section 2.1.3.2). 
  
2.1.3.1  Preparation of B104-conditioned medium for glioma cell culture 
B104 neuroblastoma cell line (Schechter et al 1984), a gift from Dr Stephen 
Rosenfeld, was recovered into warm D10 medium (DMEM w/ 4.5 g Glucose, 
w/ glutamine, w/ NaPyruvate (Gibco® Life Technologies™), 10% heat-
inactivated FBS, 1% PSA) and grown at 37°C with 5% CO2. After reaching 
confluence (2-3 days), the cells were passaged 1:10 (1 flask into 10, to 
provide high volume for harvesting the conditioned medium) and grown to 
confluence again. D10 medium was then replaced with Basal medium (see 
above Section 5.2.1), in which the confluent B104 cells were incubated for 
48 h. B104-enriched medium was then collected, filter sterilised (0.2 m pore 
size) and frozen for future use. B104 cells were incubated with fresh Basal 
media for another 48 h, collection was repeated and the B104 cells were 
discarded. 
 
2.1.3.2 Coating flasks and coverslips with Poly-L-Lysine 
Poly-L-Lysine stock (Sigma Aldrich) was diluted to 20 g/ml with sterile, 
distilled H2O and added to flasks in according volumes: 7 ml for T75, 2.5 ml 
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for T25, 1 ml for 6-well plates and 0.5 ml or less for 4-well plates. 
Flasks/plates were then incubated for > 15 min at 37 °C, the liquid was 
removed and the dishes were left to dry overnight in the incubator at 37 °C 
without tightly closing the lid if necessary. The plates and flasks were then 
stored at 4 °C degrees for further use, up to 3 months. 
 
2.1.4 Cell culture 
All cells were grown at 37°C with 5% CO2 and passaged when they reached 
about 75% confluence. To passage the cells, the medium was removed and 
the adherent cells were washed once with phosphate buffered saline (PBS, 
Gibco® Life Technologies™). Cells were then incubated with the trypsin 
substitute, TrypLE (Gibco® Life Technologies™) for 1 minute, resuspended 
in fresh medium, centrifuged at 1000 g and resuspended in fresh medium 
again, in a ratio of 1:3 to 1:5. To harvest cells for downstream analysis (i.e. 
RNA or protein extraction), cells were detached from the flask with TrypLE, 
resuspended in fresh medium, centrifuged at 1000 g and washed with PBS. 
EZ-PCR MycoplasmaTest Kit (Geneflow Ltd) was routinely used to check 
the cell lines for the presence of any mycoplasma contamination. To seed 
cells for experiments, the cell density of resuspended cells was estimated 
using a haemocytometer. 
 
2.2 GEO expression analysis 
Gene Expression Omnibus (GEO) Database is a public functional genomics 
data repository (http://www.ncbi.nlm.nih.gov/geo/). Data deposited there is 
compliant with MIAME (Minimum Information About a Microarray 
Experiment) guidelines. In the Database, array- and sequence-based data 
are accepted and tools are provided to help users query and download 
experiments and curated gene expression profiles.  
Gene expression profile GEO GSE 6919 (Chandran et al., 2007; Yu et al., 
2004), comprising 171 patient samples, was one of the largest data sets with 
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prostate cancer samples. It was also most comprehensive with regards to 
the number of myosin genes looked at, with data on 15 out of 28 non-muscle 
myosin genes that were of interest. The set included 81 samples of normal, 
benign tissue, 65 localised tumour samples and 25 samples from metastatic 
prostate cancer. The 81 “normal” samples comprised 18 normal prostate 
tissue samples free of any pathological alteration from organ donor and 63 
normal prostate tissue samples adjacent to tumour from patients. These 
were pooled together for clarity after no significant differences in myosin 
expression were noted between the two groups. Similarly to what has been 
previously described (Arjonen et al., 2014), the raw data from a microarray 
was downloaded, transformed into a log2 format and the subsets for 
different myosin isoforms were compared using statistical analysis. 
 
2.3 Reverse transcription – PCR 
2.3.1 RNA extraction 
RNA was extracted using RNeasy Mini Kit (QIAGEN) according to the 
manufacturer’s instructions. Briefly, cell pellets were collected as described 
in Section 2.1.3, washed once with PBS and centrifuged (1000 g, 5 min.). 
Pellets were lysed and homogenised in the presence of denaturing 
guanidine-thiocyanate–containing buffer (with the addition of β-
mercaptoethanol (Sigma-Aldrich)), which inactivates RNases. 70% ethanol 
was added to precipitate RNA and the lysate was applied onto a silica-based 
membrane, which was then centrifuged (10000 g, 15 sec.). In this process, 
RNA binds to the membrane while contaminants, such as the remnants of 
proteins, salts or organic compounds, are washed away. RNA was eluted in 
30 μl of nuclease-free water and a spectrophotometer (NanoDrop™, Thermo 
Scientific) was used to quantify the amount of RNA obtained by measuring 
the absorbance of the samples at 260 nm. 
 
 27 
 
2.3.2 cDNA synthesis 
cDNA was synthesised from 2 μg of RNA. The reaction mix contained: AMV 
(Avian Myeloblastosis Virus) Reverse Transcriptase (final concentration  
1 unit/μl, Promega), AMV Reverse Transcriptase Reaction Buffer (Promega), 
dNTP mix (final conc. 1 mM) (Invitrogen Life Technologies™), 0.5 μg 
Oligo(dT)15 Primers (Promega), 0.5 μg Random Primers (Promega) and 
nuclease-free water (Sigma-Aldrich). 2 μg of RNA suspended in 11 μl of 
nuclease-free water was first incubated at 65 °C for 3 minutes to remove any 
secondary structures that could impede cDNA synthesis. The reaction mix 
was then added and the mixture (total volume of 20 μl) was incubated at  
42 °C for 60 minutes, which is the optimum temperature for reverse 
transcriptase activity. The reaction was then stopped by incubating at 95 °C 
for 5 minutes to denature the enzyme. 
 
2.3.3 PCR Reaction 
Out of 39 myosin genes expressed in humans, 28 were tested. Skeletal, 
cardiac and smooth muscle myosin genes (11) were not included as we did 
not expect these genes to be expressed in non-muscle cells. Gene-specific 
primers were designed by Dr Kathryn White (Table 2.1) and used to 
determine the presence of mRNA for each of the myosin genes in the cell 
lines. 
The reaction mix contained: Taq DNA Polymerase (50 units/ml, New 
England Biolabs), ThermoPol Reaction Buffer (New England Biolabs), 
forward and reverse primers (0.4 μM each, see Table 2.1 for sequences), 
template DNA (2 μl of 2 μg/ml solution). The reaction conditions were: 
• Initial denaturation: 96 °C, 2 minutes 
• 30 cycles:  
- denaturation: 96 °C, 20 seconds 
- annealing: 54 °C, 20 seconds 
- extension: 72 °C, 20 seconds 
• Final extension: 72 °C, 7 minutes  
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Table 2.1 Sequences of primers used for PCR reactions. 
MYOSIN FORWARD (5’ → 3’) REVERSE (5’ → 3’) 
MYO1A GGCAGATTTCATCTACAAGAGCA GTTTGTGGATGGCAAATTGTT 
MYO1B GGGCTTACTGGCTTGGATCT ACAGCAACTGCATGCTTACG 
MYO1C CTCATCACCAAGGCCAAGA CCTTTATCACCGAGAATTCAGC 
MYO1D CCCTGCAGACGATTTTCAATA TGCAACCTTTGCCCTGAC 
MYO1E CAAGACCGTCCGGAACAA CCACCTGGACTGAACTGGAT 
MYO1F AGACTGTGCGCAACAACAA CGGCTGAACTGGATCTCAA 
MYO1G CTTCCACGCCTTCTACCAAT TCTCCAAGTGCAGTTCATGC 
MYO1H ATAGCCCGTGACAGACTGCT GGAGCGTTCTGGCATTTC 
NM2A TGGAGGACCAGAACTGCAA GGTTGGTGGTGAACTCAGCTA 
NM2B ATGAACCAGAAACGGGAGGT AAGGACTCCAAGAGGGGTGT 
MYO3A GAAAAATTAATCAACCTGGCAAA TGGTTGTCTCTCTGGCATGA 
MYO3B TGTCTTCTCGGATATGCCATC TGCAAGACCATTTTCTGAACC 
MYO5A GCGTCGGAGCTCTACACAA TTGAGCAGCTCTGCTGACTT 
MYO5B CCTACCAAGGCCTAAAGCAAG CCTCCTCCTCATGCTCCA 
MYO5C AAAGACCTTCACGCTTCTGG GCGGTGATCTGCACATTG 
MYO6 CTCCAGCTTCACCCGTACA CGATCTCCTGTTTCCACTATCC 
MYO7A GCTGGCAGGTCACTGAGAGT AATCACCATGGTCCCAAGTC 
MYO7B CAAGCACGCAGGGAAGTC TTTGGCTCCGTAGTTTGCTC 
MYO9A CAGATAACAAAGAAACCCCTCAG TCCACCGTGAAGCAATCC 
MYO9B CAACCAGCACATCTTCAAGC TGTTGTGCCACGTGATCC 
MYO10 AGGACTTTCCACCTGATTGC CGTGGACCTGACTCAGCA 
MYO15A ATGAACCAGAAACGGGAGGT AAGGACTCCAAGAGGGGTGT 
MYO15B GATGCCTACGGCTTTGAGG GGCTGGAGAAGAGCTGTAGG 
MYO16 CCTGCGTGAGAAGAAGGAAC CACTTTTCGGACTCCCATCT 
MYO18A GGACATGGTGACAAAGTATCAGAA TTTGACAACCAGGACTTGACC 
MYO18B AGCATGGCCATCTCATCAC TCTTGTCCTCTTCCCGAATC 
MYO19 CGCAGACCTTTCTCCAAGAG GATATGGATGGTCTCCACGAG 
HOUSEKEEPING GENES: 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
18S rRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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2.3.4 Analysis of the PCR results: agarose gel electrophoresis 
Agarose gel was prepared by dissolving agarose in TAE buffer (40 mM Tris-
Acetate, 1 mM EDTA) at 1% or 2% (w/v) concentration, depending on the 
size of the DNA fragments being compared. 0.01% ethidium bromide 
(Fischer Scientific) was added to the gel to enable the detection of DNA 
using UV light in the GelDoc Image System. The samples were loaded along 
with molecular markers of appropriate size (New England Biolabs). 
 
2.4 Real-time or quantitative PCR (qPCR) 
cDNA was synthesised as described above (Section 2.3.2). Relative myosin 
expression was monitored by Real-time PCR using SYBR® Green to detect 
the reaction product (see Table 2.1 for sequences of primers). Analysis was 
performed using BIO-RAD system and software.  
The reaction mix contained: 12.5 μl of iQ™ SYBR® Green Supermix (2x mix 
containing: dNTPs, iTaq™ DNA polymerase, MgCl2, SYBR
® Green I, 
enhancers, stabilizers, fluorescein) (BIO-RAD), 1 μl of forward and reverse 
primers (to final concentration of 0.4 μM), template cDNA (5 μl of 40 ng/ml 
solution (2 μg/ml stock solution diluted 1:50) for the samples; 5 μl of 
respective serial dilutions for the standard curves, as explained below) and 
6.5 μl nuclease-free H2O. qPCR is a method of relative quantification, and so 
standard curves were always run for reference, next to the unknown 
samples. Standard curves were prepared as follows: cDNA (2 μg/ml 
solution) from the tested specimen was mixed in equal amounts. The mix 
was then diluted 1:20 (considered 100%) and diluted into 2x serial dilutions 
of 50%, 25%, down to 3.125%. No template control (NTC) with nuclease-
free H2O instead of cDNA was included in each run. 
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The optimised reaction conditions were as follows: 
• Initial denaturation: 95 °C, 3 minutes 
• 40 cycles:  
- denaturation: 95 °C, 10 seconds 
- annealing: 65 °C, 10 seconds 
- extension: 72 °C, 30 seconds 
• Denaturation: 95 °C, 10 seconds 
• Melt curve:  65 °C to 95 °C, increment 0.5 °C per 5 seconds 
 
SYBR® Green is a general intercalating dye, so melting curves were 
included in each run to ensure reaction specificity. 
 
2.5 Antibodies 
Primary antibodies used in this study can be found in Table 2.2. 
Other used antibody and reagents include: HRP-conjugated secondary 
antibodies for western blotting (Sigma, UK), fluorescent secondary 
antibodies for immunostaining (Molecular Probes), DAPI and fluorescently-
labelled phalloidin for nuclei and F-actin staining, respectively (Sigma, UK). 
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Table 2.2 Primary antibodies used in this project. 
Specificity 
Size of the 
target [kDa] 
Organism 
Concentration 
used 
Supplier / catalogue 
number 
Myo1b 127 Rbt 
WB 1:2000, 
IF 1:100 
Sigma,  
HPA013607 
NM2A 220 Rbt 
WB 1:10000, 
IF 1:500 
Biolegend,  
PRB-440P 
Myo6 150 Rbt 
WB 1:200, 
IF 1:50 
Santa Cruz,  
sc-50461 
Myo9b 244 Rbt 
WB 1:200 
IF 1:100 
Protein Tech, 
12432-1-AP 
Myo10 237 Rbt 
WB 1:5000, 
IF 1:100 
Sigma, HPA024223 
Myo18a 233 Rbt 
WB 1:500, 
IF 1:50 
Custom made  
by Genscript  
(specific to C-term) 
ERK 44 Rbt WB 1:1000 
Cell Signalling, 
9102S 
GAPDH 36 Rbt WB 1:2000 
Sigma,  
G9545 
Paxillin 65 Mo IF 1:100 
BD Biosciences, 
#610569 
pMLC 18 Mo WB 1:500 
Cell Signaling, 
#3671 
EEA1 162 Rbt IF 1:100 
Cell Signaling, 
Antibody #2411 
DCC 158 Mo WB 1:1000 
Thermo Scientific, 
#3675S 
 
 
2.6 Western blotting 
2.6.1 Protein extraction 
Cells were harvested as described above, cell pellets were then washed 
once with PBS and centrifuged at 1000 g for 5 min. The pellet was 
resuspended in 50 μl of lysis buffer (150 mM NaCl, 0.05 M Tris (pH 8), 1% 
Triton X-100, 1 mM EDTA (pH 8) in double distilled water), which additionally 
contained protease inhibitors (Halt Protease Inhibitors Cocktail, Thermo 
Scientific Pierce), added at the time of experiment. The inhibitors included in 
this cocktail are: AEBSF, aprotinin, bestatin, E-64, leupeptin and pepstatin A. 
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Cells were incubated 30 minutes at 4 °C, with vortexing every 4-5 minutes to 
facilitate lysis. The lysates were clarified by centrifugation at 16 000 g for 20 
min (at 4 °C).  
 
2.6.2 Protein quantification 
Protein samples were quantified using the BCA assay (Micro BCA™ Protein 
Assay Kit, Thermo Scientific) according to the manufacturer’s instructions. 
Samples for the calibration curve were prepared from a stock solution of 
bovine serum albumin (BSA, 2 mg/ml), with serial solutions from 2.5 to 100 
μg/ml in distilled water. Protein extracts (diluted 1:100) and standard curve 
solutions were placed in a 96-well plate (in triplicates). An equal amount of 
working reagent was added to each well, mixed gently by shaking and 
incubated for 2 hours at 37°C. After cooling the plate to room temperature, 
the absorbance was measured at the wavelength of 540 nm using a 
colorimetric plate reader (POLARstar Optima, BMG Labtech). The protein 
concentration in the experimental samples was calculated from the 
calibration curve created with BSA standard samples. 
 
2.6.3 Separation of proteins by SDS-PAGE  
SDS-PAGE (SDS – polyacrylamide gel electrophoresis) separates proteins 
on the basis of their molecular size. To prepare the electrophoresis samples, 
40 μg of each protein sample was mixed with 2x concentrated gel loading 
(Laemmli) buffer (4% (w/v) SDS, 20% glycerol, 120 mM Tris-Cl (pH 6.8) and 
0.02% (w/v) bromophenol blue (BFB)). Samples were then denatured for  
10 min in 100 °C to use on 7.5% or 15% polyacrylamide gels. 
The stacking gel contained: 4% acrylamide/bisacrylamide (37.5:1 ratio), 125 
mM Tris-HCl (pH8), 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulfate 
(APS), 0.1% Tetramethylethylenediamine (TEMED). The separating gel mix 
contained: 7.5% or 15% acrylamide/bisacrylamide (37.5:1 ratio), 375 mM 
Tris-HCl (pH6.8), 0.1% (w/v) SDS, 0.05% (w/v) APS, 0.1% TEMED. APS 
and TEMED were added immediately before pouring the gels to catalyse 
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acrylamide polymerisation. The lower % acrylamide gels were used when 
subsequently blotting for myosin heavy chain, which has a molecular weight 
of ~200-250kDa. The higher percentage acrylamide gels were used when 
subsequently blotting for low molecular weight proteins (e.g. myosin light 
chain). 
The protein samples were loaded along with the molecular markers 
(PageRuler™ Plus Prestained Protein Ladder, Thermo Scientific) and 
electrophoresis was run at 100 V for about 2 hours. Gels were routinely run 
in duplicates, and one of each pair was stained using  Coomassie Blue or 
Instant Blue (Expedeon) and imaged using the Biorad GelDoc® Image 
System. 
 
2.6.4 Immunoblotting 
A fully submerged system was used to transfer the proteins from the gel to a 
nitrocellulose membrane with 0.45 or 0.2 m pore size, depending on the 
size of proteins analysed (Amersham™ Hybond™-ECL, GE Healthcare). 
(The lower pore size was used for low molecular weight proteins). The 
transfer sandwiches were immersed in 1 x transfer buffer (Thermo Scientific, 
#35050) and transfer for carried out at 250 mA for 1-2.5 hours, depending on 
the size of the proteins under investigation. After the transfer, membranes 
were blocked in 5% non-fat milk in PBS (w/v) for 1 hour at room temperature 
and incubated with respective primary antibody solution in 2% non-fat milk in 
PBS (w/v) (Table 2.2) at 4 ºC with rolling overnight. The membranes were 
washed in PBS with 0.05% Tween (3 times for 5 minutes, once for 15 
minutes), once with PBS for 5 minutes. Membranes were then incubated 
with HRP-labelled secondary antibody in 2% non-fat milk in PBS (w/v) for 
1.5 h at room temperature with rolling and washed as previously. 
Chemiluminescence detection was performed according to manufacturers’ 
instructions (West Pico Chemiluminescent, Thermo Scientific). The 
membranes were exposed to light sensitive (X-ray) film, with multiple 
exposure times to ensure the signal was within linear range and over-
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saturation was avoided. The films were then scanned and analysed using 
ImageJ. 
The stripping solution, Restore Western Blot Stripping Buffer (Thermo 
Scientific) was used to re-use and re-probe the membranes if required. After 
stripping, the membrane was again blocked as described above, before use 
in Western blotting.  
 
2.7 Immunostaining and imaging of fixed cells 
Cells were seeded on glass coverslips and grown according to the 
respective experiment. Cells were fixed using 2% paraformaldehyde (PFA) 
for 20 min at 37 °C, washed 3 times with PBS, permeabilised with 0.1% 
Triton X-100 in PBS for 5 min and blocked with 3% BSA in PBS (w/v) for 30 
min at room temperature. Cells were incubated with primary antibody in 3% 
BSA in PBS for 1 h at room temperature, washed 3 times in PBS with 0.05% 
Tween, 2 times with PBS and incubated with fluorescently-labelled 
secondary antibody in 3% BSA in PBS for 1 h at room temperature in the 
dark. Cells were then washed again as above and incubated for a further 20 
min in the dark with phalloidin (labelled with either Alexa Fluor 488 or 546 
(A12379 and A22283, Thermo Scientific) and DAPI in PBS, for actin and 
nuclei staining. This was followed by a final wash (as above) and mounting 
with Prolong Gold mounting medium (Invitrogen). Images of cells were 
obtained either using a Zeiss LSM700 confocal laser scanning microscope, 
using the accompanying LSM software, or using DeltaVision Deconvolution 
inverted system. Images were subsequently processed to generate figures 
using Photoshop. The images presented are representative of at least 3 
separate experiments. 
 
2.7.1 Measurements within images 
Filopodia per cell were counted manually for 20 cells in at least 3 separate 
experiments. Cell area was quantified using ImageJ, using images of cells 
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stained for actin and the ROI (Region of Interest) Manager tool. Actin 
bundles were also quantified in ImageJ using images of cells stained for 
actin. A line scan was drawn across the lamella from edge to middle of the 
cell, followed by an intensity profile and counting the peaks. 
 
2.8Transfections  
2.8.1 Transfections using small interfering RNA (siRNA) 
siGENOME siRNA  SMARTpool Human or Mouse and a non-targeting 
control (GE Healthcare Dharmacon Inc., UK) were used in this study. 
siGENOME individual siRNA reagents were also used in case of Myo10 
where specified. Following the manufacturer’s instructions, siRNA reagents 
were re-suspended to a final concentration of 10 M in siRNA buffer  
(60 mM KCl, 6 mM HEPES-pH 7.5, 200 M MgCl2). Cells were seeded at a 
density of 20 000 cells/ml in growth media, allowed to adhere to the 
coverslips/plates and grown overnight. Before transfection, growth medium 
was replaced with antibiotic-free growth medium. Lipofectamine® RNAiMAX 
Reagent (Invitrogen™, Life Technologies™, UK) was used for transfections, 
following the manufacturer’s instructions. siRNA and the transfection reagent 
were first incubated separately in serum-free media for 5 min (1 pmol for 96-
well plates, 5 pmol for 4-well plates and 25 pmol for 6-well plates) and then 
mixed at a 1:1 ratio and incubated together for 20 min at room temperature. 
The mix was then added to the cells which were grown for further 72 hours 
before analysis (i.e. staining, immunoblotting, migration assays). A time-
course experiment was first performed and it was established that optimum 
knockdown was achieved after 72 hours.  
 
2.8.2 Overexpression of GFP-labelled Myo10 
PC3 and LNCaP cells were transfected with a peGFPC2 plasmid for GFP-
Myo10 expression (Berg and Cheney, 2002). Cells were seeded at a density 
of 75000 cell/ml in growth media on glass coverslips and allowed to grow 
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overnight. FuGENE® 6 Transfection Reagent (Promega) was used for the 
transfections. Cells were then allowed to grow for 24 or 48 hours, fixed and 
immunostained as previously described (see Section 2.7). 
 
2.9 Random cell migration assay in 2D 
Cells were plated into glass-bottomed 96-well plates at 5 000 cells/well and 
transfected as described above. Cells were grown at 37°C for 48 hours, 
serum starved for 24 hours prior to stimulation with HGF (hepatocyte growth 
factor, Sigma), and then treated with HGF (25 ng/ml). The cells (a minimum 
of 3 fields for each replicate or experimental condition) were then filmed 
overnight, capturing images at 5 minutes intervals using a 20x lens (512 x 
512 total pixel size, 2 x 2 binning), and differential interference optics, on a 
DeltaVision Deconvolusion system (inverted) with motorised stage and 
incubator. Cell migration was analysed using ImageJ software (MTrackJ 
plugin).   
 
2.10 Circular invasion assay (3D-like migration) 
3D-like migration was examined using a modified circular invasion assay (Yu 
et al., 2012). Self-adhesive cell-stoppers (Ibidi, #80209) were used to create 
a cell-free space. Cells were seeded and transfected as described above 
(Section 2.5) and after 72 h, the stoppers were removed. The cells were 
then washed gently and covered with a thin layer of Matrigel (4 mg/ml). Pre-
cooled tips and tubes were used when handling Matrigel. Cells with a thin 
layer of Matrigel were left to gelify in the incubator for 20 min in 37 °C and 
then covered with normal media and allowed to grow and migrate into the 
matrix for another 24-48 hours. Cells were then fixed in 2% PFA and stained 
using standard procedures described above. 
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2.11 Statistics 
Data analysis All the data were analysed with the help of GraphPad Prism 
5.0 programme (GraphPad Software, La Jolla, California, USA) and is 
presented as mean with SD or SEM, for at least three separate experiments 
(n ≥ 3). Two-way ANOVA was used to compare differences between groups 
and statistical significance was accepted for P ≤ 0.05.  
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Chapter 3 
Myosin expression and localisation in prostate cancer 
I love rats. 
3.1 Introduction  
Cancer metastasis is a complex process that requires dramatic spatial and 
temporal reorganisation of the cell cytoskeleton (Fife et al., 2014). While the 
cytoskeleton components are well regulated in normal cells, mutations or 
aberrant expression of cytoskeletal and cytoskeleton-associated proteins are 
often observed in cancer cells (Fife et al., 2014). Myosins are an example of 
actin-associated protein family with various, isoform-specific roles in the cell 
(See Section 1.3). Among other functions, myosins play a role in cell polarity 
and motility, cell adhesion, through their functions in endocytosis and 
exocytosis they are involved in recycling of cell-adhesion molecules (Allsop 
and Peckham, 2011). 
It is therefore not surprising that some myosin isoforms have already been 
implicated in cancer. Myosin 1a (Myo1a) has been shown to be frequently 
inactivated in colorectal cancer, which results in higher tumour growth and 
accelerated progression (Mazzolini et al., 2013). Myosin 1b (Myo1b) can 
promote migration of head and neck squamous cell carcinoma (HNSCC) 
(Ohmura et al., 2015). Myosin 1e (Myo1e) is part of gene signature for 
basal-like breast cancer with poor prognosis (Hallett et al., 2012). Mutations 
in Myo1f were found in infant acute leukaemia (Duhoux et al., 2011). NM2A 
is important for breast cancer invasiveness (Derycke et al., 2011) and NM2B 
is down-regulated in non-invasive variant of melanoma cells where it is 
supposed to play a role in melanoma migration by retracting the tail during 
the migratory cycle (Jacobs et al., 2010). Both NM2A and NM2B have been 
connected with invasiveness of ovarian cancer (Iwanicki et al., 2011), 
migration of glioma (Beadle et al., 2008) and development of carcinogen-
induced tumours (Saha et al., 2011). Myosin 5a (Myo5a) is required for 
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cancer cell metastasis by affecting cell motility, and its expression levels 
positively correlate with metastatic capabilities of several human cancer cell 
lines (Lan et al., 2010).  Myosin 5b (Myo5b) is down-regulated in gastric 
cancer, which has to do with enhanced MET signalling (Dong et al., 2013). 
Genetic polymorphisms in myosin 9b (Myo9b) can play a role in aetiology of 
oesophageal cancer, by increasing the permeability of the epithelial barrier 
(Menke et al., 2012). Myosin 10 (Myo10) was recently shown to be 
upregulated in breast cancer with a role in invasiveness and metastasis 
(Arjonen et al., 2014; Cao et al., 2014) and to have a role in metastasis of 
lung cancer (Sun et al., 2015). Changes in expression and mutations of 
myosin 18b (Myo18b) have been correlated to lung, colorectal and ovarian 
cancer (Nakano et al., 2005; Tani et al., 2004; Yanaihara et al., 2004). When 
it comes to prostate cancer, so far a strong link has been found between the 
disease and myosin 6 (Myo6) (Dunn et al., 2006). Myo6 is upregulated in 
medium-grade tumours and in the LNCaP cell line, where it is involved in 
protein secretion (Puri et al., 2010). Myo6 is also overexpressed in ovarian 
cancer (Yoshida et al., 2004). 
It is worth noting that many of the described studies focus on a correlation 
between the disease and expression levels or mutations in myosins, 
whereas the detailed function of myosins in cancer progression remains 
unexplored in many cases. As pointed out in a recent review (Ouderkirk and 
Krendel, 2014), to examine the connections between myosins and cancer, it 
is important to distinguish between data from findings in vitro and genetic, 
epigenetic or transcriptomic studies of samples in vivo. A combination of 
both of these aspects can offer a strong support for a role of myosin isoform 
in tumour suppression or progression, which makes looking at the role of 
myosins in cancer an exciting area of study. At the same time, the 
complexity of processes and cytoskeleton dynamics during metastasis 
poses a great challenge. We decided to tackle this question and look at 
myosins in prostate cancer, to see by a comprehensive study if they are 
involved in tumour cell migration, invasion and metastasis. In the first part of 
the study, I looked at the expression of myosins in prostate cancer. 
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Subsequently, I sought to find out if expression levels of myosin isoforms 
change in prostate cancer models with different metastatic potential. I also 
looked at localisation of several of the upregulated isoforms.  
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3.2 Results 
3.2.1 Analysis of myosin expression in patient tissue using the 
GEO Database shows significant changes in expression for 
some myosin isoforms 
To examine expression of myosins in prostate cancer patients, I first 
performed an in silico analysis of gene expression profile of a large prostate 
cancer data set (GEO GSE6919) (Chandran et al., 2007; Yu et al., 2004). 
The high-throughput screen initially analysed almost 40,000 genes, about 
half of which were consequently discarded (genes whose expression was 
very similar throughout all the samples and genes consistently displaying 
low levels of expression that yielded high error rate). 
Among almost 20,000 genes, data on 15 myosin isoforms were available for 
analysis: MYO1A, MYO1B, MYO1C, MYO1D, MYO1E, MYO1F, MYH9 
(referred to as NM2A), MYH10 (referred to as NM2B), MYO5A, MYO6, 
MYO7A, MYO9B, MYO10, MYO16 and MYO18A. I compared the 
expression levels between normal prostate tissue, localised tumour and 
metastatic tumours, and I found significant differences in expression levels 
of 7 of the isoforms analysed (Figure 3.1).  
MYO1B and MYO10 expression increased significantly from benign tissue to 
localised tumour to metastases. Expression levels of MYO1D and MYO1F 
showed significant increase in metastatic samples in comparison to normal 
tissue. Expression of MYO5A and MYO9B increased significantly in 
localised tumours when compared to benign tissue and seemed to slightly 
decrease in metastatic tumours, although these differences were not 
significant. MYO6 levels were higher in localised and metastatic tumours 
than in normal tissue. Again, the expression levels seemed to be lower in 
metastases than in localised tumours but these differences were not 
significant. The remaining myosins (MYO1A, MYO1C, MYO1E, MYH9 
(NM2A), MYH10 (NM2B), MYO7A, MYO16 and MYO18A) have not shown 
significant differences in their expression levels. 
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Figure 3.1 Analysis of myosin isoform expression in prostate cancer 
tissue from patients, based on GEO Microarray expression profile 
(Accession number: GSE6919). Data for normal prostate tissue (n=81, blue), 
localised tumours (n=65, red) and metastatic tumours (n=25, green) 
presented on a log2 scale using box and whisker plots. Statistical analysis 
was performed using one-way ANOVA. Levels of significance are indicated 
by: p<0.05 statistically significant (*), p<0.01 very significant (**), p<0.001 
extremely significant (***).  
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Figure 3.2 Expression of TP53 and chaperones in prostate cancer 
tissue from patients, based on GEO Microarray expression profile (see 
Figure 3.1 for detailed Legend). 
 
While analysing the cohort I also checked the levels of factors commonly 
correlated with cancer: a well-known tumour suppressor TP53, a chaperone 
HSP90AA1 and, more specifically with myosins in mind, a myosin 
chaperone UNC45A (Figure 3.2). TP53 was significantly decreased in 
metastases in comparison to normal tissue and localised tumours. 
HSP90AA1 showed the contrary trend, being upregulated in metastatic sites, 
and UNC45A was significantly lower in metastases than in benign prostate 
tissue. 
 
3.2.2 Reverse-transcription PCR (rt-PCR) confirms which myosin 
isoforms are expressed in prostate cancer cell models 
Before analysing changes in myosin isoform expression in prostate cancer 
cell models, I performed reverse-transcription PCR (rt-PCR) to determine 
which myosin isoforms were expressed in these cell lines. 3 metastatic 
prostate cancer cell lines were used: LNCaP, DU145, PC3 (see Section 
1.1.3 for detailed description). These cell lines represent prostate cancer 
metastasis to lymph node (LNCaP), brain (DU145) and bone (PC3), and are 
reported to have different metastatic potential (Horoszewicz et al 1983, 
Wilson and Sinha 1997, Pulukuri et al 2005). PC3 cells have the highest 
metastatic potential in comparison to DU145 (moderate) and LNCaP cells 
(low). In addition, I tested a matched pair of cells obtained from the same 
patient, one of which was from normal prostate tissue and the other from 
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cancerous tissue from a localised prostate tumour (1535 NP and 1535 CT, 
respectively) (Bright et al., 1997). 
Rt-PCR showed that 12 myosin genes were expressed in all 5 cell lines 
tested (Table 3.1): MYO1B, MYO1C, MYO1D, MYO1E, MYH9 (NM2A), 
MYO5C, MYO6, MYO9A, MYO9B, MYO10, MYO18A and MYO19. MYO5B 
was only detected in 1535 NP and 1535 CT. MYO16 was only detected in 
PC3, 1535 NP and 1535 CT. MYO1G, MYO3A, MYO5A and MYO7A were 
only expressed in the DU145 cell line. The expression of the remaining 
myosin genes was not detected using rt-PCR in any of the cell lines. 
It is worth noting that the expression of two of the genes only expressed in 
DU145 cells is normally highly restricted to certain tissues. MYO3A 
expression is normally confined to the retina, brain, testis and sacculus 
(Dose and Burnside, 2002), and MYO7A expression is confined to the retina, 
inner ear, kidney, lung and testis (Kelley et al., 1997) with no expression in 
the brain. 
 
3.2.3 Quantitative real-time PCR (qPCR) shows some myosin 
genes are expressed at higher levels in the more metastatic 
PC3 cell lines 
As part of this project, the results for a quantitative real-time PCR (qPCR) 
analysis for LNCaP, DU145 and PC3 cell lines (performed by Dr Kathryn 
White) are presented here for completeness. The 12 myosin genes that 
were detected in all cell lines (Section 3.2.2.) were analysed using this 
approach (Figure 3.3A). This showed that the expression levels for 4 myosin 
genes MYO1B, MYO1D, MYO9B and MYO10 were highest in the more 
highly metastatic PC3 cell line compared with DU145 and LNCaP. Other 5 
myosin isoforms were highest in the DU145 cells: MYO1C, MYO1E, 
MYO9A, MYO18A, as well as NM2A, although that trend was not statistically 
significant. In contrast, expression of one myosin isoform, MYO6, was 
significantly increased in the LNCaP cell line compared with the other two 
cell lines.   
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Table 3.1 Expression of myosins in prostate cancer cell lines: LNCaP, 
DU145, PC3, 1535 NP and 1535 CT. Myosin isoforms were detected (+) or 
not detected (-) by reverse-transcription PCR. 
Myosin LNCaP DU145 PC3 1535 NP 1535 CT 
MYO1A - - - - - 
MYO1B + + + + + 
MYO1C + + + + + 
MYO1D + + + + + 
MYO1E + + + + + 
MYO1F - - - - - 
MYO1G - + - - - 
MYO1H - - - - - 
NM2A (MYH9) + + + + + 
NM2B (MYH10) - - - - - 
MYO3A - + - - - 
MYO3B - - - - - 
MYO5A - + - - - 
MYO5B - - - + + 
MYO5C + + + + + 
MYO6 + + + + + 
MYO7A - + - - - 
MYO9A + + + + + 
MYO9B + + + + + 
MYO10 + + + + + 
MYO15A - - - - - 
MYO15B - - - - - 
MYO16 - - + + + 
MYO18A + + + + + 
MYO18B - - - - - 
MYO19 + + + + + 
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We then carried out a further analysis of the matched pair of cell lines 
(1535), looking at genes with particularly high levels in the metastatic PC3 
cell line: MYO1B, MYO1E, MYO6, MYO9B, MYO10 and MYO18A. I 
determined that two of the genes, MYO1B and MYO10, again showed 
significantly higher expression levels by qPCR in the cancerous cell line 
1535 CT compared to the normal prostate cells (1535 NP) (Figure 3.3B). 
Expression of MYO1E, MYO9B and MYO18A was higher in 1535 CT but the 
differences were not statistically significant. Somewhat surprisingly, levels of 
MYO6 expression were higher in 1535 NP, but this difference was not 
statistically significant.  
The unusual expression profile of the DU145 cell (Section 3.2.2) suggested 
to us that it may not be as reliable a model for prostate cancer as the other 
cell lines tested, even though it is used quite commonly. What is more, 
DU145 has been established from a metastatic tumour in the brain, which 
almost never occurs in prostate cancer (Stone et al., 1978). We therefore 
decided to abandon routinely using DU145 cell line as a model, focusing on 
the other cell lines which represent different stages of cancer: LNCaP and 
PC3 represent metastatic cells with different metastatic potential, whereas 
1535 NP and CT model benign prostate tissue and localised cancerous 
tissue, respectively.  
 47 
 
 
Figure 3.3 Analysis of myosin expression in prostate cancer cell lines. 
(A) qPCR shows myosin expression levels for LNCaP, DU145 and PC3 
cells, relative to 18S rRNA as internal control. Bars represent mean + 
standard error, n = 3 (B) qPCR shows myosin expression levels in 1535 NP 
and 1535 CT, relative to 18S rRNA as internal control. Bars represent mean 
+ S.E., n = 3. Statistical analysis was performed using two-way ANOVA. 
Levels of significance are indicated by: p<0.05 statistically significant (*), 
p<0.01 very significant (**), p<0.001 extremely significant (***).  
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3.2.4 Western blotting (immunoblotting) confirmed changes in 
expression levels for mRNA at the protein level 
I next investigated if the increase in expression levels of the different myosin 
genes shown by qPCR (MYO1B, MYO6, MYO9B, MYO10 and MYO18A) 
was reflected by changes at the protein level by western blotting. MYO1E, 
although significantly upregulated in PC3 cells, was not included in these 
experiments as good, reliable antibodies were not available at the moment 
of the study. I also examined the expression levels of non-muscle myosin 2a 
(NMMHC-2a, referred to as NM2A), a ubiquitous, highly expressed myosin, 
which did not show changes in expression when analysed by qPCR. It 
should be noted that Myo18a has two isoforms, alpha and beta (Mori et al., 
2005), and in this study I refer to Myo18aas Myo18a. 
I found that higher levels of Myo1b, Myo9b, Myo10 and Myo18a were 
expressed in PC3 cells compared to LNCaP cells (Figure 3.4A, B). In 
contrast, levels of Myo6 were significantly higher in LNCaP than in PC3 
cells. Levels of NM2A did not change. The trends in myosin expression 
between LNCaP and PC3 cells shown by western blotting were thus similar 
to those observed by qPCR. In the matched pair of patient cells 1535 NP 
and 1535 CT, western blotting also showed a similar trend in myosin 
expression compared to that observed by qPCR, however, none of the 
differences were statistically significant (Figure 3.4C, D). Levels of Myo1b 
and Myo10 were higher in 1535 CT than in 1535 NP. Expression of Myo18a 
was slightly higher in 1535 CT, and levels of NM2A and Myo6 did not 
change. Because of time restrictions, expression of Myo9b was not looked at 
in 1535 cell lines. 
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Figure 3.4  Immunoblotting shows expression changes at the protein 
level in (A, B) LNCaP and PC3 cell lines and (C, D) matched pair of 1535 
cell lines. Examples of blots with molecular markers in kDa marked to the 
right. Total ERK was used as loading control. Quantification of expression 
relative to ERK, bars represent mean + SD for at least 3 experiments. 
Statistical analysis was performed using two-way ANOVA. Levels of 
significance are indicated by: p<0.05 statistically significant (*), p<0.01 very 
significant (**), p<0.001 extremely significant (***) 
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3.2.5 Morphology of the cell lines: prevalence of filopodia 
I stained the LNCaP and PC3 cells for actin to compare actin organisation 
and overall cell morphology. Both cell lines are of epithelial origin and are 
adherent, but their morphology shows interesting differences. The LNCaP 
cells grow in clumps or colonies and their shape is usually elongated (Figure 
3.5A). PC3 cells also have an elongated shape but they grow independently 
in a monolayer, without forming colonies (Figure 3.5B).  
There was a clear difference in the numbers of filopodia between LNCaP 
and PC3 cells. Filopodia are thin, actin-rich protrusions with a well-
established connection to cell motility (described in Section 1.2.3). PC3 cells 
exhibited numerous filopodia and some cells seemed to be connected 
through these thin protrusions, which appear to have the features of 
tunnelling nanotubes (Abounit and Zurzolo, 2012). LNCaP cells had few 
filopodia. Quantification of the number of filopodia per cell (Figure 3.5C) 
confirmed that LNCaP cells have a much lower average number of filopodia 
(0.75 ± 1.45 filopodia per cell, mean ± SD, n = 20) compared to PC3 cells 
which have a high number (15.35 ± 7.7 filopodia per cell, mean ± SD,  
n = 20). Interestingly, the increased number of filopodia in PC3 cells 
correlates directly with the increased levels of Myo10 (Figure 3.4A, B). This 
is particularly worth noting because Myo10 is a known filopodia-promoting 
factor (Bohil et al., 2006).  
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Figure 3.5  Differences in morphology of 2 prostate cancer cell lines: 
LNCaP and PC3. Low power images (upper panels) and high power images 
(lower panels) of LNCaP (A) and PC3 (B) cells stained for F-actin using 
fluorescent phalloidin. The images are shown in grey scale, reverse contrast 
for increased clarity. Scale bars as shown. (C) Quantification of filopodia per 
cell, n= 20 cells (from 3 separate experiments), bars represent mean + SD. 
Statistical analysis was performed using unpaired t-test, (***) is for p<0.001. 
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3.2.6 Immunostaining shows specific and characteristic 
localisation of each myosin isoform in each cell line 
Immunostaining was used to gain further insight into the potential differences 
in the localisation of myosins in LNCaP and PC3 cells that might correlate 
with differences in expression levels. Myo10 localises to the tips of the 
numerous filopodia in PC3 cells (arrows in Figure 3.6B and Figure 3.7C), in 
agreement with previous reports for this myosin (Bohil et al., 2006). In the 
LNCaP cells, which express low levels of this myosin, staining for Myo10 
was mostly diffuse and cytoplasmic (Figure 3.6A). Myo10 seems to localise 
to the scarce filopodia formed by LNCaP, although the staining is very weak 
and Myo10 is absent from the filopodia tips (Figure 3.7A). 
While carrying out this work, it was reported that upregulation of Myo10 is 
linked to expression of mutant p53 in breast cancer (Arjonen et al., 2014). 
Protein p53 is a well-known tumour suppressor which can gain tumour-
promoting functions when mutated (Lane and Levine, 2010). However, the 
LNCaP cells express wild-type p53 and PC3 cells are p53-null (Carroll et al., 
1993), and thus we did not find a link between Myo10 overexpression and 
expression of mutant p53. To check whether a prostate cancer cell line 
expressing mutant p53 would show any correlation, I included the DU145 
cell line into this analysis, since they express p53 protein mutated in two 
codons (Carroll et al., 1993). As shown by qPCR, Myo10 expression in 
DU145 is only slightly higher than in the LNCaP cells. DU145 cell line has 
around 8 filopodia per cell (8.75 ± 5.2 filopodia per cell, mean ± SD, n = 20), 
a number increased compared to LNCaP cells, and Myo10 localises to the 
filopodia tips (Figure 3.7B). Both Myo10 levels and filopodia numbers are still 
lower LNCaP and DU145 cells compared to the p53-null PC3 cell line.  
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Figure 3.6 Localisation of Myo10 in prostate cancer cell lines. LNCaP 
(A) and PC3 (B) cells stained for nuclei (DAPI - blue), F-actin (AF546-
phalloidin - red) and Myo10 (green). Arrows in (B) show Myo10 at the tips of 
filopodia in PC3 cells. Scale bar = 30 m. The images are representative of 
at least 3 separate experiments.  
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Figure 3.7 Localisation of Myo10 in prostate cancer cell lines (higher 
magnification). LNCaP (A), DU145 (B) and PC3 (C) cells stained for nuclei 
(DAPI - blue), F-actin (AF546-phalloidin - red) and Myo10 (green). Arrows in 
(A) show lack of Myo10 at the tips of rare, short filopodia in LNCaP cells; 
arrows in (B) show Myo10 at the tips of filopodia in DU145, and in numerous 
filopodia in PC3 cells (C). Scale bar = 5 m. The images are representative 
of at least 3 separate experiments.  
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Myo1b localised to intracellular vesicles in LNCaP cells (Figure 3.8A, 
arrows), and there was additionally some localisation to the plasma 
membrane, where it co-localised with actin (Figure 3.8A, arrowheads). In 
PC3 cells, Myo1b co-localised with actin and actin-rich areas at the plasma 
membrane, in membrane ruffles and to intracellular vesicles (Figure 3.8B, 
arrows). A similar localisation for Myo1b has been previously reported for 
other cell types (Salas-Cortes et al., 2005; Tang and Ostap, 2001), where 
Myo1b was found to be concentrated in dynamic membrane areas enriched 
with actin and associated with punctate structures in the cytoplasm. The 
intracellular vesicles were previously identified to be endosomes (Raposo et 
al., 1999; Salas-Cortes et al., 2005). In PC3 cells, there was also some 
localisation of Myo1b within the filopodia, as found in other studies (Figure 
3.8C, arrows) (Kim and Flavell, 2008; Komaba and Coluccio, 2010). The 
filopodia-like protrusions, however, were often seen between two cells, 
suggesting it could be tunnelling nanotubes (Abounit and Zurzolo, 2012), 
which can also be present in cancer cells (Ware et al., 2015). 
Neither LNCaP nor PC3 cells showed abundant actomyosin bundles close to 
the plasma membrane (Figure 3.9A, B), they also lack central stress-fibre 
bundles that are found in more adherent, non-colony forming cells such as 
fibroblasts (Vicente-Manzanares et al., 2009). NM2A in the LNCaP cell line 
had a diffuse, cytoplasmic localisation, with some co-localisation with actin 
close to the plasma membrane (Figure 3.9A, arrows). PC3 cells also showed 
some NM2A staining close to the plasma membrane, where it co-localised 
with actin (Figure 3.9B, arrows).  
I found that Myo18a localised to the cytoplasm and in membrane ruffles 
and/or close to the plasma membrane in both PC3 and LNCaP cells (Figure 
3.9C and D, arrows). This localisation is similar to that previously reported 
for Myo18a and is consistent with its role in modifying actin organisation in 
the lamellipodium (Hsu et al., 2010; Tan et al., 2008).   
 56 
 
  
Figure 3.8 Localisation of Myo1b in prostate cancer cell lines. LNCaP 
and PC3 cells stained for F-actin (AF546-phalloidin - red), nuclei (DAPI - 
blue) and Myo1b (green). Arrows in (A) and (B) show that Myo1b localises to 
vesicles; arrowhead in (A) shows Myo1b at actin-rich regions close to cell 
border in LNCaP cells; Arrows in (C) point to Myo1b localised in the 
protrusions (filopodia or tunnelling nanotubes between two cells). Scale bar 
= 30 m. The images are representative of at least 3 separate experiments. 
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Figure 3.9 Localisation of NM2A and Myo18a in prostate cancer cell 
lines. LNCaP and PC3 cells stained for nuclei (DAPI), F-actin (AF546-
phalloidin) and NM2A (A, B) or Myo18a (C, D). Arrows in A, B indicate 
NM2A co-localising with dynamic actin close to cell membrane; arrows in C, 
D show Myo18a localising close to actin-rich membrane ruffles. The images 
are representative of at least 3 separate experiments. 
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Myo6 showed a diffuse, cytoplasmic staining both in PC3 and LNCaP cells 
(Figure 3.10A and B). Myo6 has been shown to have a punctate localisation 
in LNCaP cells (Puri et al., 2010) where it co-localises with early endosomes 
and the Golgi. Using the commercial antibody (Santa Cruz), I was unable to 
observe localisation of Myo6 to vesicles. Myo9b was enriched in membrane 
ruffles/lamellipodia in PC3 cells (Figure 3.9D), consistent with its role in cell 
polarity and recruitment of RhoGAP to the lamellipodium (Hanley et al., 
2010), while the staining in LNCaP cells was diffuse and Myo9b was missing 
from actin-rich areas (Figure 3.10C). 
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Figure 3.10 Localisation of and Myo6 and Myo9b in prostate cancer cell 
lines. LNCaP and PC3 cells stained for F-actin (AF546-phalloidin - red), 
nuclei (DAPI - blue) and Myo6 (green) (A, B) or Myo9b (green) (C, D). 
Arrows in (C) indicate lack of Myo9b in actin-rich protrusions.  
Scale bar = 30 m. The images are representative of at least 3 separate 
experiments. 
 60 
 
3.3 Discussion 
The GEO analysis presented here for patient samples of prostate cancer 
suggests that the expression level of some types of myosin increases as 
cells become more metastatic. The expression levels of some myosin 
isoforms (MYO5A, MYO6, MYO9B) increased in localised tumours, while 
other increased in metastases (MYO1B, MYO1D, MYO1F, MYO10). 
Expression levels of other myosins such as MYH9 (NM2A) or MYO18A did 
not seem to change. Analysing myosin expression levels in commonly used 
prostate cancer cell lines showed a less clear cut change in myosin 
expression. However, an increased level of Myo10 expression in the more 
highly metastatic PC3 cell line was linked to a high level of filopodia, with 
Myo10 localised to the filopodial tips and Myo1b only found in filopodia in the 
PC3 cells. These results raise the possibility that myosin expression level 
and organisation in prostate cancer cell lines are able to influence their 
phenotype. 
Two myosin isoforms, Myo1b and Myo10, showed a clear, significant 
increase in expression in metastases, in tissue arrays and from the analysis 
of prostate cell lines by qPCR. Of particular interest was the increased 
expression of Myo10 in PC3 cell line, which mirrors the increase of Myo10 in 
metastatic tumours, observed in the GEO analysis. Myo10 has a well-
established role in formation of filopodia, which are directly associated with 
cell migration (Sousa et al., 2006). We observed a 2.9-fold increase in levels 
of Myo10 in highly malignant PC3 cells in comparison to LNCaP cell line. 
Interestingly, even though Myo10 is widely expressed in a variety of 
vertebrate tissues, it is quite sparse as it comprises of only about 0.0005% of 
total protein in cells (Berg et al., 2000). It is therefore not surprising that a 3-
fold difference has an appreciable effect on the phenotype. The connection 
of Myo10 to filopodia can also be seen in our study, where protein levels of 
Myo10 (Figure 3.4) correlate neatly with numbers of filopodia in each cell 
line (Figure 3.5).  
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Upregulation of Myo10 has recently been linked to mutant p53 expression 
and invasiveness, where Myo10 was found to be a necessary downstream 
component for mutant p53-driven invasion in breast cancer and pancreatic 
carcinoma (PDAC) cells (Arjonen et al., 2014). Mutant p53 is a stable variant 
of p53 protein, a well-known tumour suppressor and high levels of mutant 
p53 are often associated with cancer (Lane and Levine, 2010). In metastatic 
prostate cancer p53 is often either mutated or lost (Chen et al., 2005). An in 
silico analysis of the GEO data showed a significant decrease of TP53 gene 
in metastatic sites (Figure 3.2). Although highly malignant PC3 cells do not 
express p53 (Carroll et al., 1993), I have found that they still express high 
levels of Myo10 and have numerous filopodia. At the same time, LNCaP 
cells, which show almost no filopodia and low levels of Myo10, express 
normal p53 (Horoszewicz et al., 1983). DU145 cells, which express low 
levels of Myo10 and show medium numbers of filopodia per cell, express 
mutant p53 (Carroll et al., 1993). Taken together, these results confirm that 
there is no link between expression of Myo10 and mutant p53 in prostate 
cancer cells, and that the connection between Myo10 and p53 observed in 
other studies seems therefore to be cancer type-specific. 
Levels of Myo1b were clearly increased in metastatic prostate cancer – both 
in patient tissue and when measured in the cell lines by qPCR and western 
blotting. Out of the matched pair of patient cell lines, 1535 CT had visibly 
higher levels of Myo1b in comparison to normal prostate tissue. Myo1b has 
a role in formation of post-Golgi carriers and in transport of endocytic 
organelles (Raposo et al., 1999; Salas-Cortes et al., 2005). The role of 
Myo1b in cancer has not been well investigated, although it was recently 
found to be upregulated in head and neck squamous cell carcinoma 
(HNSCC) (Ohmura et al., 2015). The same group observed slight 
upregulation of Myo1b in prostate cancer and other types of cancer, 
suggesting that the role of Myo1b in different cancers required further 
investigation (Ohmura et al., 2015). Here, immunostaining has shown that 
Myo1b localises to the actin-rich areas at the plasma membrane, vesicles 
(endosomes) and, somewhat surprisingly, to the filopodia of PC3 cells. Other 
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groups have previously observed similar Myo1b localisation in other cell 
types: Myo1b-eGFP and endogenous Myo1b were found to co-localise with 
actin at the cell periphery, in cytoplasmic punctae and endosomes in normal 
rat kidney epithelial cells and in human melanoma cell line (Salas-Cortes et 
al., 2005; Tang and Ostap, 2001). Interestingly, Myo1b has also been found 
at dynamic actin structures, such as membrane ruffles and large protrusions 
and filopodia / invadopodia in HeLa cells (Kim and Flavell, 2008; Komaba 
and Coluccio, 2010). One of the groups found that motor function and 
binding to phosphatidylinositol 4,5-bisphosphate (PIP2) was necessary for 
Myo1b to localise to filopodia (Komaba and Coluccio, 2010), suggesting that 
binding of Myo1b to phosphoinositides played a role in regulating Myo1b 
localisation to actin-enriched membrane projections.  
Expression of Myo18a observed in the GEO Database was similar across 
different samples, not showing any changes. We did, however, notice 
intriguing changes in the qPCR analysis, the difference between LNCaP and 
PC3 being one of the most obvious, more than 40-fold, as well as a 
noticeable change in the western blotting. The possible role of Myo18a in 
cell migration has been described through its interaction with kinases (Hsu et 
al., 2010). MYO18A was also found in a three-way translocation of Histone-
lysine N-methyltransferase 2A gene (MLL or KMT2A) MLL in child acute 
myeloid leukaemia (Ussowicz et al., 2012). An interesting interaction 
between Myo18a and NM2A, which has many roles in the cell, has recently 
been described (Billington et al., 2015), and will be discussed further in 
Chapter 4. As mentioned previously, Myo18a has two isoforms, alpha and 
beta (Mori et al., 2005). The isoforms show several differences: Myo18a is 
expressed in most tissues, while expression of Myo18a is restricted to 
hematopoietic cells; Myo18alacks a PDZ (PSD-95/Discs-Large/ZO-1) 
domain towards the N-terminus, and therefore has a molecular weight of 
around 190 kDa, in comparison to 230 kDa for Myo18a (Mori et al., 2005). 
Antibodies used in this study to recognize Myo18a were raised against C-
terminus of the protein, but they identified a protein of about 230 kDa, 
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present in prostate tissue (not hematopoietic). This means that the 
recognised isoform expressed in examined cells was Myo18a. 
Looking at patient tissue, levels of Myo9b were significantly higher in primary 
tumours than in normal prostate, as shown by the in silico analysis. Myo9b 
was also significantly upregulated in the malignant PC3 cells, as shown by 
qPCR and immunoblotting. The observed staining, with Myo9b localising to 
lamellipodia and membrane ruffles was consistent with its role in cell polarity 
(Hanley et al., 2010). Myo9b contains in its tail a RhoGAP (GTPase 
Activating Protein) domain (Reinhard et al., 1995), which regulates the Rho 
GTPases, which in turn play a major role in actin reorganisation (Ridley et al 
2003). Myo9b has been connected to progression of oesophageal cancer 
(Menke et al., 2012), and another class 9 isoform, Myo9a, has been 
implicated in migration of epithelial cells (Omelchenko and Hall, 2012). This 
together suggested that Myo9b could be an interesting isoform to explore 
further in context of metastasis. 
Aggressive, metastatic prostate cancer samples showed increased 
expression of several myosin isoforms, but an interesting exception to this 
trend is Myo6, which is highly expressed in localised tumours (Figure 3.1, 
GEO Microarrays). Myo6 is also the only isoform with expression levels 
significantly higher in the LNCaP cells with low metastatic potential in 
comparison to the highly metastatic PC3 cells. This is in agreement with 
earlier findings that Myo6 is frequently overexpressed in prostate and breast 
cancer tissues (Su et al., 2001), with higher levels detected in medium-grade 
androgen-dependent prostate cancers than in more advanced and 
aggressive cancers (Dunn et al., 2006). Loss of Myo6 has been shown to 
reduce the motility of ovarian and prostate cancer cells (Dunn et al., 2006; 
Yoshida et al., 2004), but it is unclear why it is present in very low levels in 
the malignant PC3 cell line. Our immunostaining showed a diffuse, 
cytoplasmic localisation of Myo6 in both LNCaP and PC3 cell lines. Myo6 
has been previously reported to localise to protrusions and membrane ruffles 
(Yoshida et al., 2004), as well as in the perinuclear region around the Golgi 
complex and on endocytic structures (Aschenbrenner et al., 2003; Buss et 
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al., 1998; Maddugoda et al., 2007; Puri et al., 2010). The different staining 
patterns observed depend on the set of antibodies used (commercial or in-
house), and may explain the observed differences between the staining 
pattern we observed and those from other groups. Additionally, one group 
used pre-treatment with saponin, a gentle detergent, to remove the 
unbound, overexpressed Myo6 from LNCaP cells, but the approach was not 
successful in our study (results not shown). 
The connection between Myo6 and human cancer, including prostate 
cancer, has been relatively well explored. It has been suggested that 
because of its role in endocytosis, Myo6 could contribute to cancer cell 
motility by promoting internalisation and recycling of key mediators such as 
integrins and other receptors (Yoshida et al., 2004). Another group showed 
overexpression of Myo6 as an example of molecular alterations of the Golgi 
apparatus in human prostate cancer, with the functional significance to be 
fully characterised (Wei et al., 2008). Since Myo6 levels are highest in 
medium-grade prostate cancers, Dunn and colleagues noted that advanced 
cancers may gain other properties and become less dependent on Myo6 
(Dunn et al., 2006). For example, Myo6 stabilizes E-cadherin, which is 
crucial in border cell migration (Geisbrecht and Montell, 2002), a mode 
employed by well-differentiated prostate cancers. On the other hand, 
advanced prostate cancers show perturbed E-cadherin-mediated cell 
adhesion and express lower levels of E-cadherin (De Marzo et al., 1999). As 
a result, as (Dunn et al., 2006) speculate, Myo6 can be necessary for 
regulating migration of medium grade, E-cadherin-positive prostate cancers, 
but may not be as critical in more advanced cancers (Dunn et al., 2006). 
Finally, one study looked specifically at Myo6 in androgen-dependent 
LNCaP cells (Puri et al., 2010). Importantly, the authors found no connection 
between androgen receptor translocation into the nucleus and Myo6 
expression. They observed that Myo6 is involved in secretion of the 
prostate-specific marker, PSA, and the vascular endothelial growth factor, 
VEGF. PSA can increase cellular migration (by either promoting EMC or by 
cleaving ECM proteins), and VEGF is a key angiogenic factor that mediates 
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the recruitment and cell proliferation of endothelial precursor cells. 
Therefore, an increase in PSA and VEGF secretion caused by Myo6 
overexpression could be a significant factor promoting tumour growth or 
enhancing cell motility. At present, however, it is unclear why Myo6 is 
speciﬁcally overexpressed in these secretory adenocarcinomas and how 
exactly upregulation of secretion generates a malignant tissue (Puri et al., 
2010). 
Using the GEO Database to analyse expression of myosins has the 
disadvantage that many genes in the GEO Database were discarded before 
the final analysis (see Section 2.2). Thus some of the myosin isoforms 
detected by rt-PCR in the cell lines are missing in the GEO analysis 
(MYO5B, MYO9A and MYO19). In addition, we did not detect additional 
myosin isoforms identified in patient samples in the GEO database by PCR 
(MYO1A, MYO1F, NM2B, MYO5A, MYO7A). This could be due to a different 
detection threshold of the methods used. Moreover, cancers are very 
diverse and cell lines do not represent all the possible scenarios found in the 
clinic.  
Choosing an appropriate model is crucial for designing relevant experiments, 
which is why I considered all of the cell lines tested here. Even though the 
DU145 cell line is a popular prostate cancer model, it originates from a 
metastatic tumour in the brain, which very rarely occurs in a typical course of 
prostate cancer (Kaighn et al., 1981). rt-PCR analysis of this cell line showed 
that it had an unusual expression profile, with expression of MYO7A and 
MYO3A, myosins that normally only have a restricted tissue expression 
(Coluccio, 2008; Dose and Burnside, 2002; Richardson et al., 1997; Weil et 
al., 1995). Thus, we decided to discontinue using this cell line as a model. 
The LNCaP cells, originally obtained from a tumour in the lymph node, are 
still androgen-sensitive and maintain their malignant properties 
(Horoszewicz et al., 1983). They represent an ‘early’ stage of prostate 
cancer metastasis. The commonly used PC3 cell line is derived from an 
osteolytic metastatic site, which is the most common metastatic site for 
prostate cancer – up to 90% of reported metastases (Bubendorf et al., 2000; 
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Doctor et al., 2014). PC3 cells are already androgen-independent and 
therefore represent a more aggressive phase of cancer cell development 
(Kaighn et al., 1981). PC3 cells do form tumours when injected into nude 
mice (Ma and Waxman, 2009; Pulukuri et al., 2005). In contrast, LNCaP 
cells, do not normally form tumours or metastasise (Wu et al., 1994), 
although there is evidence showing that subpopulations of LNCaP cells form 
tumours in mice (Hurt et al., 2008). Cell lines, even though they have 
obvious limitations, are a useful first step in elucidating molecular 
mechanisms of processes and in identifying potential subjects of interest for 
further research. Because of its insensitivity to androgens and high level of 
malignancy, PC3 cell line is a good model for the study and evaluation of 
metastases of human prostate carcinomas. This is why I chose to focus the 
consequent study of myosins in prostate cancer on this cell line. 
Taken together, the findings from the GEO Database analysis, as well as the 
subsequent analysis of myosin expression by rt-PCR, q-PCR and western 
blotting for a variety of prostate cancer cell lines, I have decided to choose 
four isoforms as the most interesting candidates for further investigation: 
Myo1b, Myo9b, Myo10 and Myo18a. Myo1b and Myo10 are overexpressed 
in both metastatic prostate cancer and in the more highly metastatic PC3 cell 
lines, compared to LNCaP cells, and thus might be expected to contribute to 
the metastatic phenotype. Myo18a is overexpressed in PC3 cells, though not 
in metastatic prostate cancer tissues, but it worthy of further investigation as 
its overexpression may contribute to the PC3 cell phenotype.  
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Chapter 4 
Role of myosins in prostate cancer cell migration 
 
4.1 Introduction 
After analysing expression of myosins in prostate cancer tissue and cell 
lines, I have decided to further focus on four myosin isoforms: Myo1b, 
Myo9b, Myo10 and Myo18a. Experiments focusing on Myo9b were started 
towards the end of the project, and due to time restrictions this myosin 
isoform could not have been fully investigated. General information about 
myosin domains and structure can be found in the introduction (section 1.3). 
The structure of myosins of interest is described in more detail below, since 
looking at structure of the protein can offer a valuable insight into its possible 
mechanism of action. 
Myo1b belongs to class 1 and, like all the class 1 myosins, it has a basic 
myosin tail homology 1 (MyTH1) domain in its tail, which contains a 
pleckstrin homology (PH) domain-like fold (Figure 4.1) (Hokanson et al., 
2006). The PH domain binds selectively to phosphatidyl inositol 
phospholipids (PIPs) (Lemmon and Ferguson, 2001; Tacon et al., 2004), 
and all of the class 1 myosins can bind to PIPs in vesicles and/or in the 
plasma membrane (Lin et al., 2005; Raposo et al., 1999; Ruppert et al., 
1993; Salas-Cortes et al., 2005). Myo1b binds PtdIns(4,5)P2 and 
PtdIns(3,4,5)P3, with higher affinity for PtdIns(4,5)P2 (Komaba and Coluccio, 
2010). 
Myo9b, which forms class 9 together with Myo9a, is not a very well-studied 
myosins isoform but certainly an interesting one. Myo9b contains a RhoGAP 
(GTPase activating protein) domain in its tail (Bement et al., 1994; Reinhard 
et al., 1995). The Rho family of small GTPases includes Rho, Rac and 
CDC42 which cycle between GTP-bound active and GDP-bound inactive 
states. GAPs partially control this by stimulating intrinsic GTP hydrolysing 
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activity of Rho GTPases, inhibiting them by facilitating the shift into inactive 
state (Jaffe and Hall, 2005). Rho GTPases are involved in actin 
reorganisation and various actomyosin-dependent processes, including 
regulation of the protrusion and retraction mechanisms (Ridley and Hall, 
1992; Ridley et al., 2003). Head domain of Myo9b contains quite an unusual 
N-terminal extension of about 60 amino acids, only found in class 9 myosins, 
and its neck region contains 4 IQ motifs (Figure 4.1) (Wirth et al., 1996). 
Myo9b is highly expressed in leukocytes and shows low to moderate level of 
expression in various tissues including spleen, small intestine, testis, 
prostate, brain and others (Wirth et al., 1996).  
Myo10, the only member of class 10, is widely expressed in vertebrate 
tissues, with high levels in developing brain, endothelia and many epithelia 
(Berg et al., 2000; Courson and Cheney, 2015). The tail of Myo10 has three 
PH (pleckstrin homology) domains, a myosin tail homology 4 (MyTH4) 
domain and a band 4.1/ezrin/radixin/moesin (FERM) domain (Figure 4.1) 
(Berg et al 2000). In myo10, the PH domains are responsible for binding of 
this myosin to PIPs, specifically to PtdIns(3,4,5)P3 and PtdIns(3,5)P2 and this 
is required for Myo10-induced filopodial formation (Plantard et al., 2010; 
Tacon et al., 2004), although the underlying molecular mechanism is unclear 
(Liu et al., 2012). The MyTH4 domain is involved in microtubule binding 
(Kerber and Cheney, 2011; Weber et al., 2004), which could mean that 
Myo10 acts as a potential motorised link between actin filaments and 
microtubules. The FERM domain binds β1, β3 and β5 integrins, receptors 
important for cell adhesion, and is thought to be required for transporting the 
integrins to the filopodia tips, which contributes to stability and functionality 
of the protrusions (Zhang et al., 2004). The initial sequence analysis of 
Myo10 identified a putative coiled-coil region in the tail, so the heavy chains 
were predicted to dimerise as a coiled coil. Our lab demonstrated that it is 
actually a stable single -helix (SAH) (Knight et al., 2005), although more 
recently it has been suggested that the distal region of this sequence may 
allow Myo10 to form anti-parallel dimers (Lu et al., 2012). 
 69 
 
Myo18a together with Myo18b forms class 18. An interesting feature of 
Myo18a is its ATP-insensitive actin binding site in its N-terminal domain 
(Figure 4.1), which suggests that Myo18a might act as a dynamic actin 
tether (Guzik-Lendrum et al., 2013; Isogawa et al., 2005). The N-terminal 
domain contains also a PDZ (PSD-95/Discs-Large/ZO-1) domain, known to 
act as a scaffold for holding signalling protein complexes together. Myo18a 
dimerises through a coiled-coil region in the tail, similarly to myosin 2. These 
two myosins share other similarities, such as two IQ motifs which bind 
essential and regulatory light chain (ELC and RLC) (Guzik-Lendrum et al., 
2013). However, Myo18a does not form filaments like myosin 2 (see Section 
1.3.2), as it lacks the repeating sequences of positive and negative charges 
along its coiled coils that promote the assembly of myosin tails into filaments 
in myosin 2 (Guzik-Lendrum et al., 2013). 
In the second part of the study, I further investigated the putative role of 
Myo1b, Myo9b, Myo10 and Myo18a in prostate cancer. To find out more 
about the function of these myosin isoforms, I used RNA interference (RNAi) 
technology to knock down myosins in the highly metastatic PC3 cell line. I 
then determined the effects of the knockdown on the morphology and 
behaviour of PC3 cells. These included changes in cell shape and area, in 
organisation of actin cytoskeleton and changes in the status of filopodia and 
focal adhesions. Finally, I looked at endocytosis and migration in 2D and 3D-
like environment. 
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Figure 4.1 Diagrammatic representations of Myo1b, Myo9b, Myo10 and 
Myo18a (adapted with permission from (Allsop and Peckham, 2011)). 
Detailed description of the structural features of each myosin in the main 
text. 
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4.2 Results 
 
4.2.1 siRNA-mediated knockdown depletes myosin expression 
I used siRNA to knock down the endogenous levels of four myosins Myo1b, 
Myo9b, Myo10 and Myo18a, in the highly metastatic PC3 cell line. As seen 
in Chapter 3 (Figure 3.3, 3.4), the PC3 cells normally express high levels of 
these myosins, and depletion can help determine how endogenous myosin 
expression affects cell morphology and behaviour. The efficiency of siRNA 
(SMARTpool and single reagents) knockdowns was confirmed by western 
blotting (Figure 4.2).  
To establish the best time point for knockdown efficiency, I first ran a time-
course experiment for Myo10 knockdown (Figure 4.2A). Levels of Myo10 
were decreased by 90% after 72 hours and below the level of detection after 
96 hours when using SMARTpool siRNA. Considering that the cells reached 
very high confluence after 96 hours, I used 72 hours as the standard time-
point for analysis of any effects of knockdown, where I was better able to 
analyse cell shape in subconfluent cultures. I also confirmed that the 
depletion was efficient for the other myosin isoforms (Figure 4.2B). Figure 
4.2B also shows that knockdown of a particular myosin did not affect levels 
of the remaining myosins, including NM2A, which confirms specificity of the 
knockdowns. Myo9b was the last myosin isoform analysed, and because of 
time restrictions its knockdown has been quantified separately, in 
comparison to GAPDH (Figure 4.2C). This also serves to show that GAPDH 
gave similar results to ERK as a loading control. 
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Figure 4.2 siRNA-mediated knockdown of myosins in highly metastatic 
PC3 cell line. A. Time-course experiment for knockdown of Myo10 using 
siGENOME SMARTpool siRNA (Thermo Scientific) after 24, 48, 72 and 96 
hours; and with a single siRNA reagent (siRNA3) after 72 and 96 hours, 
analysed by immunoblotting. B. Knockdown of Myo1b, Myo10 and Myo18a 
in PC3 cell line using siGENOME SMARTpool siRNA after 72 hours, 
analysed by immunoblotting confirms that myosin levels are significantly 
reduced while levels of other myosins are not affected. C. Knockdown of 
Myo9b using siGENOME SMARTpool siRNA after 72 hours. Control cells 
were treated with non-targeting siRNA (NT). Molecular weight markers 
shown to the right. Total ERK (A, B) or GAPDH (C) were used as loading 
control. 
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4.2.2 Knockdown of Myo10 reduces the number of filopodia 
Actin staining revealed that knockdown of myosins results in isoform-specific 
changes in cell morphology (Figure 4.3A). Most interestingly, knockdown of 
Myo10, but not the other myosins, significantly reduced the numbers of 
filopodia by more than 70% (to 4.2 ± 0.84 filopodia per cell, mean ± S.E.M., 
n=20) in comparison to control cells (13.1 ± 1.26 filopodia per cell, mean ± 
S.E.M., n=20, p < 0.05) (Figure 4.3B).  
Knockdown of each of the myosins increased the cell spread area of PC3 
cells significantly, by about 2-3 fold (Figure 4.3A, C). Cell shape was also 
changed, with Myo1b and Myo10 knockdown resulting in a more polygonal 
shape, and Myo9b and Myo18a knockdown resulting in a more rounded 
shape, with prominent membrane ruffles around the edges in case of 
Myo18a depletion, and an actin-rich area at the cell periphery in Myo9b-
depleted cells (Figure 4.3A, arrows). These different results suggested that 
each myosin isoform affects the organisation of actin cytoskeleton in a 
distinct way. 
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Figure 4.3 Knockdown of myosins affects morphology of PC3 cells.  
A. Low power images of PC3 and myosin-depleted PC3 cells (after 72 h) 
stained for F-actin using fluorescent phalloidin to show changes in cell area. 
The fluorescent images are shown in reverse contrast for increased clarity. 
Arrows in the Myo9b KD picture indicate peripheral high density actin 
staining. Arrows in the Myo18a KD picture show numerous membrane 
ruffles. Scale bar = 90 μm or as shown. The images are representative of at 
least 3 separate experiments Control cells were treated with non-targeting 
siRNA (NT). B, C. Quantification of filopodial number (B) and cell area (C), 
bars represent mean + S.E. for n=20 cells from at least 3 separate 
experiments. Statistical analysis was performed using two-way ANOVA. 
Levels of significance are indicated by: p<0.05 statistically significant (*), 
p<0.01 very significant (**), p<0.001 extremely significant (***).  
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To ensure that myosins were being inhibited specifically, and that the 
observed changes were not just a result of off-target effects, I also looked at 
the effect of individual siRNA reagents for Myo10 in PC3 cells. As shown by 
immunoblotting (Figure 4.2B), using individual siRNAs resulted in about 75% 
decrease in levels of Myo10, comparable to SMARTpool, which is a mix 
containing 25% of each of the 4 individual siRNA sequences. Furthermore, 
knockdown by individual reagents in PC3 cells resulted in similar phenotype 
changes (Figure 4.4A), including significantly decreased numbers of 
filopodia (Figure 4.4B) and an increase in cell area (Figure 4.4C). All types of 
treatment produces morphological changes similar to previous SMARTpool 
knockdown, with formation of actin stress fibres and loss of filopodia, which 
confirmed that the observed results are connected specifically to depletion of 
Myo10. This confirmed that the use of SMARTpool is efficiently and 
specifically knocking down the myosin of interest. 
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Figure 4.4 Knockdown of Myo10 by individual siRNA reagents.  
A. Control and myosin-depleted PC3 cells (after 72 h) stained for F-actin 
using fluorescent phalloidin to show changes in cell area. The fluorescent 
images are shown in reverse contrast for increased clarity. Treatment with 
individual siRNA reagents (siRNA3 as an example) results in the same 
morphology changes as in case of SMARTpool, although some smaller cells 
with filopodia are also visible (arrow points to filopodia). Control cells were 
treated with non-targeting siRNA (NT). Scale bar = 30 μm. The images are 
representative of at least 3 separate experiments. B, C. Quantification of 
filopodial number (B) and cell area (C), bars represent mean + SD for n=20 
cells from at least 3 separate experiments. Statistical analysis was 
performed using two-way ANOVA, p<0.001 extremely significant (***).  
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4.2.3 Myo10 overexpression in prostate cancer cells increases the 
numbers of filopodia 
Considering the striking reduction in filopodia number after Myo10 
knockdown in PC3 cells, I then overexpressed Myo10 fused to GFP (Green 
Fluorescence Protein) (GFP-Myo10) to see whether increased levels of 
Myo10 will correlate with higher filopodia numbers. Myo10 overexpression 
has been shown to increase filopodia numbers in several cell lines (Berg and 
Cheney, 2002; Bohil et al., 2006), but not in prostate cancer cells. I 
overexpressed GFP-Myo10 in both PC3 cell line and the more benign 
LNCaP cells, characterised in Chapter 3 (Figure 4.5A). Similarly to 
endogenous Myo10, GFP-Myo10 localised to the tips of filopodia. Both cell 
lines overexpressing GFP-Myo10 showed increased numbers of filopodia in 
comparison to control cells. This was particularly visible in the LNCaP cell 
line where overexpression of GFP-Myo10 resulted in a significant increase, 
from 0.2 ± 0.6 filopodia per cell (mean ± SD, n=10) to an average of 9.2 ± 
1.81 filopodia per cell, (mean ± SD, n=10, p < 0.05) (Figure 4.5B). These 
results confirmed that numbers of filopodia correlate with levels of Myo10. 
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Figure 4.5 Overexpression of Myo10-EGFP results in increased number 
of filopodia in LNCaP and PC3 cell lines. A. LNCaP and PC3 cells stained 
for F-actin (AF546-phalloidin, red) and nuclei (DAPI, blue).  
Scale bar = 20 μm. The images are representative of at least 3 separate 
experiments. B. Bars represent mean + SD quantified for n = 10 cells, from 3 
separate experiments. Statistical analysis was performed using two-way 
ANOVA, (**) is for p<0.01. 
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4.2.4 Knockdown of Myo1b, Myo9b, Myo10 and Myo18a affects 
focal adhesions in PC3 cell line 
Staining of myosin-depleted PC3 cells for actin and paxillin, a component of 
the focal adhesion complex (Turner, 2000), showed changes to focal 
adhesions and organisation of the F-actin cytoskeleton that depended on 
which myosin was knocked down. Control PC3 cells do not show prominent 
focal adhesions and typically contain low numbers of actin stress fibres 
(Figure 4.6A). After Myo1b depletion long stress fibres appeared throughout 
the cell and the ends of the stress fibres were associated with large, well-
developed focal adhesions (Figure 4.6B, arrows). Myo9b-depleted PC3 cells 
were rounded, with numerous focal adhesions around the cell edges, some 
of them at the end of actin bundles (Figure 4.6C, arrows). Shorter, more 
central stress fibres were visible after knockdown of Myo10, and the ends of 
some of these stress fibres were associated with large focal adhesions 
(Figure 4.6D, arrows). In contrast, in Myo18a depleted cells, somewhat 
centripetal stress fibres were found in the lamella, where they were arranged 
parallel to the plasma membrane. Numerous prominent focal adhesions 
could be observed at the edges of the cell (Figure 4.6E, arrows). Moreover, 
a line profile analysis of the frequency of actin bundles in the lamella showed 
that the frequency of bundles was significantly reduced for Myo1b 
knockdown cells (2.1 ± 0.1 bundles per micron, mean ± S.E.M., n=9) 
compared to controls (2.6 ± 0.2 bundles per micron, mean ± S.E.M., n=9, 
p<0.5%). These results suggested to us that each myosin is able to affect 
the organisation of the actin cytoskeleton in a distinct way, and in particular 
to influence actin filament and focal adhesion formation. 
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Figure 4.6 Effect of myosin knockdown on focal adhesions of PC3 
cells. Control (A) and Myo1b (B), Myo9b (C), Myo10 (D) and Myo18a (E) 
knockdown PC3 cells stained for F-actin (phalloidin – red), paxillin (green) 
and nuclei (DAPI – blue). Arrows indicate large focal adhesions at the ends 
of F-actin bundles (arrowed) in knockdown cells. Scale bar = 30 μm. Red 
lines in (A, B) represent an example of line for the profile analysis of the 
frequency of actin bundles described in Section 4.2.4  
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4.2.5 Isoform-specific changes in NM2A organisation after 
silencing myosins 
Staining of cells for actin filaments and non-muscle myosin 2a (NM2A), 
which is a component of stress fibres, revealed interesting, isoform-specific 
changes in each of the knockdowns. Control PC3 cells typically show a 
punctate distribution of NM2A filaments throughout the cell, with some co-
localisation with actin filaments and the scarce stress fibres (Figure 4.7A, 
arrows and at higher magnification in Figure 4.8A). After Myo1b knockdown, 
NM2A filaments co-localised with the prominent long stress fibres (arrows in 
Figure 4.7B and Figure 4.8B). Following knockdown of Myo9b, visible stress 
fibres appeared across the whole cell area, with NM2A co-localising to the 
stress fibres. The cells also showed a distinctive actin-rich area at the cell 
periphery, from which NM2A was largely missing (Figure 4.7C, arrows in 
Figure 4.8C). Some co-localisation of actin and NM2A was also observed in 
Myo10-depleted PC3 cells (arrows in Figure 4.7D and Figure 4.8D).   
But perhaps the most interesting changes appeared after knocking down 
Myo18a. The dense, centripetal actin filaments in the lamella were 
associated with a large visible increase in NM2A filaments (arrows in Figure 
4.7E and Figure 4.8E). We found this trend really interesting, especially in 
light of the recent finding that Myo18a levels can affect the organisation of 
NM2A (Billington et al., 2015). It is worth noting that, as shown in section 
4.2.1, knockdown of Myo1b, Myo10 and Myo18a did not affect the 
expression levels of NM2A (Figure 4.1B), and thus the changes in NM2A 
organisation we observed are not due to changes in NM2A expression 
levels. Finally, immunoblotting for phosphorylated light chain did not show 
any changes in levels of phosphorylation (Figure 4.9). This suggested that 
NM2A had not become activated by knockdown of Myo1b, Myo10 or 
Myo18a, but was being re-organised. Knockdown of Myo9b, however, 
seems to increase phosphorylation of myosin light chain, in agreement with 
Myo9b RhoGAP function and with what has been observed before for 
Myo9b knockout mice (Figure 4.9) (Hanley et al., 2010).  
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Figure 4.7 Effect of myosin knockdown on cytoskeleton and NM2A 
organisation in PC3 cells. Control (A) and Myo1b (B), Myo9b (C), Myo10 
(D) and Myo18a (E) knockdown PC3 cells stained for F-actin (phalloidin – 
red), non-muscle myosin 2A (NM2A, green) and nuclei (DAPI – blue). The 
arrows indicate stress fibres and actin bundles in cells. Scale bar = 30 μm   
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Figure 4.8 Effect of myosin knockdown on cytoskeleton and NM2A 
organisation in PC3 cells. Control (A) and Myo1b (B), Myo9b (C), Myo10 
(D) and Myo18a (E) knockdown PC3 cells stained for F-actin (phalloidin – 
red), non-muscle myosin 2A (NM2A, green) and nuclei (DAPI – blue). The 
arrows indicate stress fibres and actin bundles in cells. Scale bar = 5 m 
except for Myo9b KD (B) where the scale bar = 2 m   
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Figure 4.9 Levels of Phosphorylated Myosin Light Chain (pMLC) in PC3 
cells. Levels of pMLC in control and Myo1b, Myo10 and Myo18a depleted 
PC3 cells, analysed by immunoblotting. Due to time restrictions, Myo9b 
knockdown has been analysed separately (I performed the experiment and 
Professor Michelle Peckham has done the immunoblotting). Control cells 
were treated with non-targeting siRNA (NT). Molecular weight markers 
shown to the right. Total ERK or GAPDH (Myo9b) were used as loading 
control.  
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4.2.6 Knockdown of myosins reduces cell migration in 2D and 3D-
like environment 
The changes to the actin cytoskeleton resulting from depletion of Myo1b, 
Myo9b, Myo10 and Myo18a raised the possibility that their depletion might 
also affect cell migration. Due to time restrictions, cell migration after Myo9b 
knockdown was not analysed during this project. As for the other myosin 
isoforms, overnight time-lapse microscopy and cell-tracking of HGF-
stimulated PC3 cells in a 2D random migration assay showed that depletion 
of Myo10, but not Myo1b or Myo18a, affected cell migration speed, with 
tracks from Myo10-depleted cells visibly shorter than control cells (Figure 
4.10A). Myo10 knockdown reduced cell speed significantly, by about 2 fold, 
from 0.49 ± 0.24 m/min to 0.25 ± 0.1 m/min (mean ± SD, n=50, p < 0.05) 
(Figure 4.10B). Directional persistence, defined as the ratio between 
displacement and the total path length, was not affected by knockdown of 
Myo1b or Myo10, but was significantly decreased in Myo18a depleted cells, 
by about 30% from 0.34 ± 0.18 to 0.26 ± 0.12 (mean ± SD, n=50, p < 0.05) 
(Figure 4.10C), suggesting a role for Myo18a in determining directionality of 
migration.  
Using a circular invasion assay that closely mimics 3D invasion (Yu et al., 
2012), I observed that control PC3 cells migrate freely into the matrix, 
whereas migration of myosin depleted cells is visibly decreased (Figure 
4.10D). The control cells (NT, treated with non-targeting siRNA) migrated 
into cell-free area at the rate of about 26.5 ± 4.9 cells per square 250 m x 
250 m (mean ± SD). For the same surface area, the rate for Myo1b 
knockdown cells was 2.6 ± 2.6, 1.4 ± 2.3 after Myo10 knockdown, and 
Myo18a knockdown resulted in 6.1 ± 5.2 cells on average migrating into the 
area (n=10 measured fields of view from at least 2 experiments). As 
represented by the pictures, inhibition of invasion into the cell-free Matrigel 
was most evident in the case of Myo10 (Figure 4.10D).  
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Figure 4.10 Effect of myosin knockdown on cell migration. A. Coloured 
lines show representative tracks for individual cells during an overnight time-
lapse microscopy experiment for control (treated with non-targeting siRNA, 
NT) and Myo1b, Myo10 and Myo18a-depleted cells after HGF stimulation. 
Scale bar = 100 μm. B, C. Quantification of speed (B) and directional 
persistence (C) of cell migration, bars show mean + SD for n = 50 cells from 
at least 3 experiments (NT = control cells treated with non-targeting siRNA). 
Statistical analysis was performed using one-way ANOVA. Levels of 
significance are indicated as: p<0.05 for statistically significant (*), p<0.01 
very significant (**), p<0.001 extremely significant (***). D. Circular invasion 
assay showing cells stained for actin filaments (phalloidin - green) and nuclei 
(DAPI - blue). Dashed line marks the border of cell-free space created by 
stoppers. Scale bars as shown. The images are representative of at least 3 
separate experiments.  
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4.2.7 Knockdown of Myo1b affects endocytosis in PC3 cell line 
As previously mentioned, Myo1b plays a role in endocytosis (Salas-Cortes et 
al., 2005), so I looked at this process in PC3 cells using immunostaining for 
EEA1 (early endosome antigen 1), a well-known marker for early 
endosomes (Figure 4.11A). As a control, I also tested endocytosis in cells 
depleted of Myo10, which is not thought to be involved in endocytosis. 
Knockdown of Myo1b, but not Myo10, resulted in noticeable decrease of 
EEA1-positive vesicles in PC3 cells. This is quantified in Figure 4.11B, 
confirming a statistically significant decrease of early endosomes in Myo1b-
depleted cells, while endocytosis in Myo10 KD cells was not affected. 
Ideally, these results should be accompanied by assays looking at uptake of 
particles, but several attempts at experiments using fluorescent dextran or 
transferrin were unsuccessful and their outcomes inconclusive (data not 
shown).  
 
4.2.8 Knocking down DCC, a Myo10 regulator, changes 
morphology of PC3 cells 
As a further test of the involvement of Myo10 in the increase in filopodia, I 
investigated the effect of knockdown of one of its known binding partners. 
Myosins can be regulated by various factors and binding partners (see 
section 1.3.4), and Myo10 interacts with Deleted in Colon Cancer (DCC) 
(Zhu et al., 2007), which promotes movement of Myo10 along actin filaments 
and enhances Myo10-mediated elongation of basal filopodia (Liu et al., 
2012). I silenced DCC in PC3 cells using siRNA (Figure 4.12A). 
Interestingly, analysis of immunostained PC3 cells after DCC knockdown 
showed an increase in cell area and loss of filopodia (quantified data not 
shown, representative images in Figure 4.12B, C). These effects are similar 
to depleting Myo10 and suggest a role for DCC in regulating Myo10 in 
prostate cancer cells. It would be interesting to see the effect of DCC on cell 
migration, although preferably efficiency of the knockdown should be 
optimised first, since knockdown of DCC reduced the protein levels only by 
about 60% in comparison to non-targeting control (Figute 4.12A).  
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Figure 4.11 Knockdown of Myo1b affects endocytosis in PC3 cells.  
A. PC3 cells stained for endosome marker, early endosome antigen (EEA1, 
red) actin filaments (phalloidin - green) and nuclei (DAPI - blue). White 
squares represent example areas where measurements were made for 
quantification (squares 20m x 20 m). Scale bar as shown. The images are 
representative of at least 3 separate experiments. B. EEA1-positive vesicles 
per square 20m x 20 m quantified. Bars show mean + SD for n=25 fields 
from at least 3 experiments. Statistical analysis was performed using one-
way ANOVA. (***) is for p<0.001.   
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Figure 4.12 Knockdown of DCC affects the morphology of PC3 cells.  
A. Knockdown of DCC and Myo10 in PC3 cells using siGENOME 
SMARTpool siRNA after 72 hours, analysed by immunoblotting to confirm 
efficiency. Control cells were treated with non-targeting siRNA (NT). 
Molecular markers shown to the right. Total ERK was used as loading 
control. B. PC3 cells stained for F-actin (phalloidin, green), Myo10 (red) and 
nuclei (DAPI – blue). Scale bar = 20 m. The images are representative of at 
least 3 separate experiments. 
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Our functional studies relied primarily on siRNA technology and off-target 
effects cannot be fully excluded unless a rescue experiment is performed. 
However, two transient transfections (siRNA silencing and overexpression of 
GFP constructs) in succession are very challenging to complete 
successfully, and all my attempts resulted in very high cell death. In addition, 
siRNA-resistant constructs were not available for all the myosins of interest. I 
also found that four individual Myo10 siRNA sequences, each led to a similar 
phenotype (i.e. filopodia loss) (Figure 4.4), and this is distinct from the 
phenotype observed with Myo1b, Myo9b or Myo18a siRNA, arguing against 
off-target effects. Therefore, I concluded that it is unlikely that the off-target 
effects played a dominant role in mediating the biological effect of the 
knockdowns. 
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4.3 Discussion 
The results presented here show that siRNA-mediated knockdown of 
Myo1b, Myo9b, Myo10 and Myo18a have isoform-specific effects on 
morphology and migration of PC3 cell line. High endogenous expression 
levels of Myo10 in PC3 cells are linked to high numbers of filopodia, and a 
more migratory phenotype as shown by immunostaining and cell migration 
assays. High levels of Myo1b influence cell morphology and actin 
organisation, with sparse long actin stress fibres appearing in Myo1b-
depleted PC3 cells, but only contribute to cell migration in 3D, not 2D. High 
levels of Myo9b are linked to low levels of stress fibres and Myo9b 
knockdown increases the appearance of numerous focal adhesions. High 
expression levels of Myo18a affect cell morphology and organisation of 
NM2A, and contribute to 3D migration as well as to directional persistence of 
2D cell migration. Overall, this subset of myosins might contribute to the 
migratory phenotype of PC3 cells, with Myo10 being the most important 
myosin for metastasis of prostate cancer. 
Our knockdown and overexpression experiments confirm a clear relation 
between levels of Myo10 and numbers of filopodia, already observed in 
Chapter 3 when comparing different cell lines. Knockdown of DCC, Myo10 
activator, also resulted in loss of filopodia, offering a further confirmation of 
this link. It has been shown previously that Myo10 is a strong promoter of 
filopodia formation. Overexpressing full-length Myo10 has been shown to 
increase the number and length of filopodia in previous studies, both for 
substrate attached filopodia, dependent on adhesion and Myo10’s ability to 
bind integrins (Berg and Cheney, 2002; Watanabe et al., 2010; Zhang et al., 
2004), and for dorsal filopodia, independently of adhesion or integrin binding 
(Bohil et al., 2006). It has been suggested that the Myo10 tail is mostly 
responsible for stimulating filopodia formation, through a variety of 
mechanisms. These include regulation of motor activity through a motor – 
tail interaction (Umeki et al., 2011) and/or transporting proteins that are 
important for filopodia formation, such as integrins (Bohil et al., 2006). More 
recent reports show that Myo10 is also required for the formation of other 
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actin-based protrusions such as invadopodia and podosomes (McMichael et 
al., 2010; Schoumacher et al., 2010).  
Prostate cancer cells have been reported to exhibit motile responses to HGF 
(Parr et al., 2001; Wells et al., 2005). The reduction in PC3 cell migration in 
2D HGF stimulated migration assays resulting from Myo10 knockdown, 
suggests that Myo10-dependent filopodia formation could be important for 
cell motility. As some cells lacking filopodia are still able to migrate 
(Lundquist, 2009), it has been suggested that filopodia are not essential for 
migration, but promote it, by exploring the environment, and enabling cells to 
decide where to go. Our experiments with PC3 cells, also show that filopodia 
are not absolutely required for cell migration, as even in the absence of 
filopodia, the Myo10-depleted cells were able to move in 2D migration 
assays, albeit more slowly than control cells.  
The increase in cell area we observed when Myo10 is knocked down is 
consistent with that reported previously for other cell types (Bohil et al., 
2006), where overexpression of Myo10 resulted in a significant reduction in 
cell area, and siRNA knockdown of Myo10 in HeLa cells resulted in a ~4 fold 
increase in cell area. It is unclear why Myo10 knockdown results in large 
central stress fibres, which have the appearance of thick bundles, 
reminiscent of bundles of actin in filopodia. However, fascin, an actin 
bundling protein found in filopodia is known to be overexpressed in PC3 
cells (Darnel et al., 2009). Inhibition of fascin blocks filopodial formation 
(Huang et al., 2015). If levels of fascin remain high following Myo10 
knockdown, but filopodia are unable to form, fascin may be able to bundle 
actin filaments in the cell body producing the large central stress fibres we 
observed. 
Our finding that Myo10-dependent filopodia are likely to be important for cell 
migration agrees with the recent findings that Myo10-dependent filopodia are 
important for breast cancer metastasis (Arjonen et al., 2014; Cao et al., 
2014). Myo10 was found to be upregulated in aggressive subtypes of breast 
carcinoma, and it was shown to be required for breast cancer cell adhesion, 
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migration and invasion in vitro, and to regulate dissemination of breast 
cancer cells in vivo in a mouse model (Arjonen et al., 2014; Cao et al., 
2014). In this case, Myo10-induced cell adhesion, migration, and invasion 
were dependent on stabilization of filopodia that protrude into the matrix 
using the cell adhesion receptor β1 integrin.  
One of these groups also reported a new link between Myo10 upregulation 
and mutant p53 expression (Arjonen et al., 2014). Mutant p53, a stable 
variant of p53 (resulting from gain-of-function mutations), is associated with 
increased metastasis, and overexpression of Myo10 is linked to expression 
of p53 in clinical breast cancer samples. Silencing of mutant p53 
downregulated Myo10 expression levels, through the MAPK/ERK pathway, 
as inhibiting this pathway was also able to downregulate Myo10 expression 
levels. In addition, mutant p53 is also associated with an increase in the 
transcription factor ERG1 (early growth response protein 1), and ERG1 
binds to the Myo10 promoter (Arjonen et al., 2014), thus providing a link 
between p53 and Myo10 expression levels. However, PC3 cells do not 
express p53, while they still have high levels of Myo10 expression (Carroll et 
al., 1993).  Therefore, in these cells there must be some other mechanism 
by which Myo10 levels are increased. 
We found that Myo18a affects PC3 cell morphology, migration and 
organisation of actin and NM2A, indicating that Myo18a contributes to cell 
motility. The large re-organisation of actin and NM2A induced by Myo18a 
knockdown may have two possible explanations; its interaction with non-
muscle myosin 2 (NM2A) and its interaction with Myotonic dystrophy kinase-
related Cdc42-binding kinase (MRCK; (Tan et al., 2008)) through the leucine 
rich adaptor protein LRAP35a. Myo18a associates with MRCK, which is 
linked to Cdc42, and works with ROCK to phosphorylate MYPT1 (myosin 
phosphatase target subunit-1). MYPT1 inhibits myosin light chain 
phosphatase (MCP1), thereby increasing MLC2 (myosin light chain 2) 
phosphorylation (Wilkinson et al., 2005), and should therefore increase the 
activity of NM2A and thus cell contractility.  The association of MRCK with 
Myo18a is suggested to increase MLC2 phosphorylation, and increase 
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NM2A assembly in the lamella. MRCK knockdown resulted in a loss of 
lamellar NM2A –actin networks, while Rho mediated stress fibres remained. 
A similar effect was observed when Myo18a was depleted. However, this is 
not consistent with our finding that knockdown of Myo18a in PC3 cells 
results in an increase in NM2A filaments in the lamella. 
Recently, Myo18a was additionally found to interact directly with NM2A in 
vitro, co-assembling into mixed bipolar filaments both in vitro and in vivo 
(Billington et al., 2015). Moreover, this interaction resulted in shorter NM2A 
filaments in vitro (Billington et al., 2015), suggesting that Myo18a is able to 
affect the size and organisation of NM2A filaments. NM2A filaments are 
~314nm long, but mixed NM2A/Myo18a filaments are only 227 nm long. The 
failure to observe this in vivo using super-resolution microscopy was 
attributed to the low levels of Myo18a expression compared to NM2A. 
However, they pointed out that the ratio of Myo18a to NM2A could be higher 
in some cell types or subcellular locations (Billington et al., 2015), in which 
case effects on filament organisation might be observed. This suggests that 
the re-organisation of NM2A that we found to result from Myo18a 
knockdown results from a reduction in the direct interaction between Myo18a 
and NM2A, rather than changes in levels of light chain phosphorylation, or 
levels in NM2A expression.  
Myo18a has also been identified as an interacting partner for the p21-
activated kinase (PAK) though the βPIX/GIT1 complex (Hsu et al., 2010). 
That study showed that knockdown of Myo18a increased the size of focal 
adhesions, increased cell area and the cells became more rounded with 
dense, centripetal actin filaments, similar to the findings reported here. 
These authors suggested that when Myo18a is knocked down, PAK2 
becomes relocalised to focal adhesions contributing to their increase in size 
and number, and the enlarged morphology observed, and that a lower focal 
adhesion turnover explains their lower motility. Consistent with these results, 
we also found that Myo18a knockdown increases the number of cell 
adhesions. Myo18a has also been reported to be required for cell migration 
in 2D and 3D (Hsu et al., 2014; Hsu et al., 2010; Tan et al., 2008), in 
 95 
 
agreement with our findings that Myo18a knockdown affects directional 
persistence in 2D migration assays, and reduces migration in 3D migration. 
High levels of Myo9b expression in PC3 cells are likely to contribute to lack 
of stress fibres, and thus to enhanced cell migration. The RhoGAP domain in 
Myo9b tail inhibits Rho, which reduces the downstream activity of ROCK (a 
Rho kinase). This in turn increases myosin light chain (MLC) phosphatase 
activity, resulting in lower levels of MLC phosphorylation, thus reducing actin 
stress fibre formation. This would mean that Myo9b knockdown, by 
increasing Rho activity, should increase stress fibre formation and MLC 
phosphorylation, and it’s what was observed in this study. Genetic variation 
in Myo9b has recently been associated with an increased risk of esophageal 
adenocarcinoma, although its exact role remained undefined (Menke et al., 
2012). Even though I did not look at cell migration of Myo9b-depleted cells in 
this project, such analysis was subsequently done by my group and showed 
that Myo9b knockdown significantly decreased cell migration in 2D and 3D, 
further confirming a potential role for Myo9b in motility of prostate cancer 
cells (Makowska et al., 2015). 
Our screening data suggested that Myo1b might also play a role in 
metastasis, and knockdown of this myosin affects cell migration in 3D, cell 
shape and morphology, as well as endocytosis.  Myo1b regulates actin 
assembly at various regions in the cell including the production of post-Golgi 
carriers (Almeida et al., 2011; Gillespie et al., 2001), endocytic organelle 
transport (Cordonnier et al., 2001; Raposo et al., 1999), and in maintaining 
cortical tension at the plasma membrane, where it specifically associates 
with dynamic, non-tropomyosin containing actin filaments (Coluccio and 
Geeves, 1999; Tang and Ostap, 2001). High endogenous levels of Myo1b in 
more highly metastatic cells might therefore increase cortical tension 
allowing cells to move through stiff extracellular matrices in vivo, perhaps 
explaining why knockdown of Myo1b affects migration in 3D, but not on a 2D 
surface. 
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Myo1b has been recently shown to regulate cell motility in human head and 
neck squamous cell carcinoma (HNSCC) (Ohmura et al., 2015). In this 
study, downregulation of Myo1b inhibited metastasis to lymph nodes in a 
model using nude mice. Consistent with our observations, Myo1b 
knockdown in HNSCC was shown not to affect the filopodia, and the authors 
suggested that Myo1b contributes to cancer cell motility through its role in 
the formation of large protrusions at the leading edges of cells (Ohmura et 
al., 2015). Epithelial to mesenchymal transition (EMT) is one of the 
mechanisms of cancer progression, including migration and invasion, the 
researchers also investigated the relation between Myo1b expression and 
some EMT-related molecules, but found no connection, concluding that 
Myo1b has a role in cell motility of HNSCC independent of major EMT 
transcription factors but through a different mechanism (Ohmura et al., 
2015). 
Myo1b has been associated with other types of protrusions than filopodia. 
Some of the protrusions where Myo1b has been observed seem to resemble 
tunnelling nanotubes, which have recently been observed in pancreatic 
cancer cells (Ware et al., 2015). It would be interesting to explore the role of 
Myo1b in these structures, especially that Myo1b plays a role in elongating 
membrane tubules (Almeida et al., 2011; Yamada et al., 2014). Although we 
did not see that Myo1b knockdown affects filopodia, Myo1b was reported to  
contribute to formation of so called ‘repulsive filopodia’ (Prosperi et al., 
2015). Myo1b interacts with EphB2 receptor, and Eph receptors together 
with their ligands, ephrins, are important for cell segregation and cell 
repulsion (Astin et al., 2010). Myo1b is required to initiate the formation of 
long, thin EphB2-enriched filopodia at the interface of ephrinB1 and EphB2 
cells (Prosperi et al., 2015). Myo1b may also regulate membrane tension by 
coupling cortical acto-NMM2 network to the plasma membrane (Diz-Munoz 
et al., 2010) and thus contributes to cell repulsion by regulating NMM2 
distribution (Prosperi et al., 2015). Authors of this study speculate that 
similarly to its role for coupling the actin cytoskeleton to organelle 
membrane, Myo1b may couple mechanically the contractile acto-NMM2 
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fibres to the plasma membrane after its phosphorylation by EphB2 (Almeida 
et al., 2011; Prosperi et al., 2015; Yamada et al., 2014). 
To conclude, these results show that Myo1b, Myo9b, Myo10 and Myo18a all 
contribute to the morphology and/or migration of highly metastatic PC3 cell 
line. Each myosin has an isoform-specific effect on actin organisation, and 
their increased expression in cells with high metastatic potential may allow 
them to work collectively. Together, they help generate a cell with multiple 
protrusions that is better able to migrate through a 3D matrix. In particular 
Myo10, which is important for filopodia in prostate cancer cells as well as in 
breast cancer, is likely to be important for metastasis in a broad range of 
tumours. Many different drugs have now been developed that can inhibit 
specific myosin isoforms including those in classes 1, 2, 5 and 6 (Bond et al., 
2013), and our results additionally suggest that developing drugs to block 
specific myosin function could be useful in preventing metastasis. 
Importantly, these results emphasise that myosins not only use actin as 
tracks to walk along, but are able to actively drive actin organisation in cells. 
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Chapter 5 
Myosins in other tissues 
 
5.1 Introduction 
After analysing myosins in prostate cancer in detail, two major questions 
have arisen: what is the myosin status in non-malignant prostate tissue and 
do myosins also play a role in other types of cancer. In this final 
experimental chapter, I have addressed both these questions: I have 
analysed a cell line representing benign prostate tissue and investigated 
myosins in a glioblastoma cell culture model.  
 
5.1.1 Benign prostatic hyperplasia 
One example of non-malignant prostate tissue is the BPH-1 cell line, which 
is derived from benign prostatic hyperplasia (BPH). This is a very common 
prostate disorder, affecting approximately 70% of men over the age of 70 
(McVary, 2007). BPH is not considered to be a precursor of prostate cancer 
or a premalignant lesion, although the association between the two diseases 
remains unclear (Orsted and Bojesen, 2013). It is likely that although BPH 
does not increase the chances for prostate cancer development, it may 
increase the chance of diagnosing an incidental cancer (Chang et al., 2012).  
 
5.1.2 Glioblastoma 
Tumours of the central nervous system (CNS) can arise from several 
different cellular lineages that include glia, such as astrocytes and 
oligodendrocytes (Ostrom et al., 2014). Glioblastoma is the most common 
and most malignant of all glial tumours (grade IV astrocytoma), accounting 
for 60% of all of them (Ostrom et al., 2014). Malignant gliomas 
(glioblastomas) are primary brain tumours that are resistant to therapy and 
often have poor prognosis (Buckner et al., 2007; Stupp et al., 2007). 
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Interestingly, gliomas rarely metastasise outside the CNS, but they are 
capable of spreading long distances within the brain (Beadle et al., 2008; 
Burger and Kleihues, 1989). This limits effectiveness of local therapies and 
contributes to the high mortality rate seen in these tumours (Lim et al., 
2007). 
Moving glioma cells face particular mechanical constraints in the CNS 
environment they invade, which is packed tightly and has extracellular 
spaces in the sub-micrometre range (Thorne and Nicholson, 2006). The 
exact mode of migrating remains poorly understood. Migration of neural 
progenitor cells before they mature into neurons and glia provides some 
insight into the process: these cells utilise a unique, two-step mechanism not 
described in non-CNS-derived cells: continuous extension of a long finger of 
cytoplasm and separated, salutatory bursts of movements of the cell body 
(Bellion et al., 2005; Kakita and Goldman, 1999; Schaar and McConnell, 
2005). However, changes in development of the brain can affect this 
process, so the mechanism of migration through adult brain has not been 
fully characterised (Beadle et al., 2008). It remains unclear whether invasion 
of the brain by human glioma cells occurs by mechanisms used by other 
non-CNS cells, such as carcinomas, the unique mechanism used by neural 
progenitor cells or in an entirely different way. 
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5.2 Results 
5.2.1 Levels of myosins in Benign Prostatic Hyperplasia (BPH-1) 
I first investigated the expression levels of different myosin isoforms in BPH-
1 cell line. I focused on the myosins previously analysed in prostate cancer 
cell lines (Chapter 3) by immunoblotting Myo1b, NM2A, Myo6, Myo10 and 
Myo18a (Figure 5.1A). Myo9b was not involved in the analysis due to time 
constraints. I found that levels of Myo10 were quite high in BPH-1 cells, in 
comparison, about 50% of what I observed in the PC3 cell line. Myo1b 
expression was particularly high in the BPH-1 cell line, almost 2-fold higher 
than in PC3 cells. Levels of Myo6 and Myo18a were low, comparable to PC3 
cell line (Figure 5.1A and B), and expression of Myo6 were still significantly 
higher in LNCaP cells than the other cell lines. Expression levels of NM2A 
(Figure 5.1) were similar across the examined cell lines (Section 3.2.4). 
I also stained the BPH-1 cells for actin to investigate their overall 
morphology, in particular how actin is organised in these cells and the 
number of filopodia (Figure 5.1C). BPH-1 cells are adherent, rounded and 
grow in round-shaped colonies. Actin filaments are mostly found in bundles 
at the cell borders (Figure 5.1C). The cells display numerous protrusions and 
some ruffles, including protrusions that overlap with the neighbouring cells in 
the colonies. An analysis of filopodia number showed that BPH-1 cells have 
on average 8.1 ± 3.4 filopodia per cell (mean ± SD, n=20), although their 
ability of forming tight colonies can account for some inaccuracies in 
measurement. It is worth noting that this is on average 2 times less filopodia 
per cell than in PC3 cell line (15.35 ± 7.7, see Section 3.2.5), and this ratio 
correlates accurately with the expression levels of Myo10 in BPH-1 and PC3 
cells. 
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Figure 5.1 Myosins in BPH-1 cell line. A. Representative immunoblots for 
a range of myosins in BPH-1. Similar amounts of protein were loaded for 
each blot. Total ERK used as loading control. Molecular markers shown to 
the right. B. Quantification of expression relative to ERK, bars represent 
mean + SD for at least 3 experiments. Statistical analysis was performed 
using two-way ANOVA. Levels of significance indicated by: p<0.05 
statistically significant (*). Data from Figure 3.4 (LNCaP and PC3 cell lines) 
included for comparison. C. Low power (left) and high power (right) images 
of BPH-1 cells stained for F-actin using fluorescent phalloidin to show their 
morphology. The fluorescent images are shown in reverse contrast for 
increased clarity. Black arrows indicate actin bundles around the colonies 
and between cells. White arrow shows filopodia. Black arrowhead indicates 
a membrane protrusion. Scale bars as shown. The images are 
representative of at least 3 separate experiments.  
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5.2.2  Localisation of myosins in BPH-1 cell line 
Next, I used immunostaining to look at the localisation of myosin isoforms in 
BPH-1 cell line. Similarly to PC3 cells, Myo10 in BPH-1 cells localised to the 
tips of filopodia and protrusions (arrows in Figure 5.2D and Figure 5.3D). 
Myo1b is localised close to the plasma membrane between neighbouring 
cells and in membrane ruffles (Figure 5.2A and arrow in Figure 5.3A). NM2A 
co-localised with F-actin bundles at the border of cells towards the edges of 
the colonies (arrows in Figure 5.2B and Figure 5.3B), unlike in prostate 
cancer cell lines LNCaP or PC3. Myo6 showed a somewhat diffuse staining 
in BPH-1 cells (Figure 5.2C and Figure 5.3C) and Myo18a localised to 
membrane ruffles at the border of colonies (arrows in Figure 5.2E and 5.3E). 
The nuclear staining observed for Myo18a was unexpected and may be non-
specific. 
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Figure 5.2 Localisation of myosins in BPH-1 cell line. BPH-1 cells 
stained for F-actin (AF546 phalloidin – red), nuclei (DAPI – blue) and 
myosins: 1b (A), NM2A (B), Myo6 (C), Myo10 (D) and Myo18a (E).  
Scale bar = 30 m. White squares show areas zoomed in in Figure 5.3. The 
images are representative of at least 3 separate experiments.  
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Figure 5.3 Localisation of myosins in BPH-1 cell line (zoomed in 
images from Figure 5.2). BPH-1 cells stained for F-actin (AF546 phalloidin 
– red), nuclei (DAPI – blue) and myosins: Myo1b (A), NM2A (B), Myo6 (C), 
Myo10 (D) and Myo18a (E). Scale bar = 10 m. The images are 
representative of at least 3 separate experiments.  
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5.2.3 Knockdown of myosins in benign prostate cell line, BPH-1  
When looking for potential therapeutic targets, it is crucial that they have 
effect over cancer cells while leaving normal, benign cells unaffected. While I 
already confirmed in the previous chapters that Myo1b, Myo10 and Myo18a 
are important for morphology and behaviour of malignant prostate cancer 
cells, I wanted to look at the effect of depleting benign prostate cells of these 
myosin isoforms. Using the same siRNA technology as described previously, 
I knocked down Myo1b, Myo10 and Myo18a in BPH-1 cells (Figure 5.4). 
Staining of BPH-1 cells for paxillin, part of the focal adhesion complex, 
revealed that control BPH-1 cells have numerous, well-developed focal 
adhesions (Figure 5.5A), in contrast to highly motile PC3 cells which do not 
show prominent focal adhesions (Chapter 4). The number or size of focal 
adhesions does not change following the knockdown of Myo1b, Myo10 or 
Myo18a (Figure 5.5B–D).  
Staining the BPH-1 cells for NM2A and F-actin showed some changes after 
myosin knockdown, although not nearly as drastic as seen in cancer PC3 
cells. Control BPH-1 cells show NM2A staining around the border of the cells 
and at the periphery of the colonies, where it co-localises with actin-rich 
areas. The cells at the border of the colony exhibit filopodia and wide 
protrusions, which contain actin and NM2A at their base, and only actin 
towards the edges (Figure 5.6A, arrows). After knockdown of Myo1b or 
Myo10 BPH-1 cells showed dense actin bundles at the edges of the cells (at 
the border between cells) and at the edge of the colonies, with NM2A co-
localising with the actin-rich areas (Figure 5.6B and C). These bundles were 
more prominent in myosin-depleted cells than in control cells. After 
knockdown of Myo1b or Myo10, the cells maintained broad, short 
protrusions containing NM2A at their base. Some differences were visible in 
Myo10-depleted cells, namely they had noticeably increased cell area, 
although exact quantification was hindered due to the fact that BPH-1 cells 
grow in tight colonies and often overlap. Filopodia numbers following Myo10 
knockdown decreased by about 35% and were unaffected in cells lacking 
Myo1b (data not shown). 
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Figure 5.4 siRNA-mediated knockdown of myosins in BPH-1 cells. 
Knockdown of Myo1b, Myo10 and Myo18a in BPH-1 cell line using 
siGENOME SMARTpool siRNA after 72 hours, analysed by immunoblotting. 
Control cells were treated with non-targeting siRNA (NT). Molecular weight 
markers shown to the right. Total ERK was used as loading control. 
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Consistent with what was observed in PC3 cells (Section 4.3.5), Myo18a 
knockdown in BPH-1 cells affected organisation of NM2A, increasing the 
formation of NM2A filaments (Figure 5.7). The filaments seemed to be 
associated along centripetal actin filaments (Figure 5.7A and B, arrows), 
however these were not as clearly visible as in Myo18a-depleted PC3 cells. 
The cells had broad protrusions at the border of the colonies, withNM2A 
filaments at their base and actin-rich, NM2A-free area towards the edge 
(Figure 5.7A and B, arrowheads). Interestingly, Myo18a knockdown slightly 
decreased the numbers of filopodia in BPH-1, by about 20%, although this 
was not statistically significant (data not shown). 
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Figure 5.5 Knockdown of myosins in BPH-1 cells has no visible effect 
on focal adhesions. Control (A) and Myo1b (B), Myo10 (C) and Myo18a (D) 
knockdown BPH-1 cells stained for F-actin (phalloidin, red), paxillin (green) 
and nuclei (DAPI – blue). Arrows indicate large focal adhesions at the cell 
periphery. Control cells were treated with non-targeting siRNA (NT). Scale 
bar = 30 μm, expect for Myo1b panel (B), where the scale bar is 15 μm. The 
images are representative of at least 3 separate experiments. 
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Figure 5.6 Effect of myosin knockdown on cytoskeleton and NM2A 
organisation in BPH-1 cells. Control (A) as well as Myo1b (B) and Myo10 
(C) knockdown BPH-1 cells stained for F-actin (AF546-phalloidin – red), 
non-muscle myosin 2A (NM2A, green) and nuclei (DAPI – blue). The arrows 
in panel (A) indicate actin-rich protrusions. Control cells were treated with 
non-targeting siRNA (NT). Scale bar = 30 μm. The images are 
representative of at least 3 separate experiments. 
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Figure 5.7 Effect of Myo18a knockdown on cytoskeleton and NM2A 
organisation in BPH-1 cells. BPH-1 cells after Myo18a knockdown, stained 
for F-actin (AF546-phalloidin – red), non-muscle myosin 2A (NM2A, green) 
and nuclei (DAPI – blue). White square in panel (A) shows the area zoomed 
into in panel (B). The arrows indicate centripetal actin bundles in cells, 
arrowheads point to actin-rich protrusions where NM2A is missing. Control 
cells for this experiment shown in Figure 5.6A. Scale bars as shown. The 
images are representative of at least 3 separate experiments. 
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5.2.4 Knockdown of Myo9a in benign prostate cell line, BPH-1 
I next wanted to check if knockdown of any other myosin isoforms would 
have an effect on the benign cells. BPH-1 cells grow in connected colonies, 
so I looked at another myosin isoform which was not picked up by the 
general screen (see Chapter 3), Myo9a, which has a role in cell-cell 
junctions in epithelial cells (Omelchenko and Hall, 2012). In the preliminary 
screen, Myo9a has been shown by qPCR to be upregulated in the DU145 
cell line (Figure 3.2), which also grows in rounded colonies. Interestingly, 
knocking down Myo9a brought quite drastic changes to BPH-1 cells, 
contrary to other myosins (Myo1b, Myo10 and Myo18a) examined in section 
5.2.3. In contrast to control BPH-1 cells, which grow in tight colonies (Figure 
5.8A), cells after Myo9a knockdown where much more scattered (Figure 
5.8B). This is in agreement to what has been observed before that Myo9a 
regulates collective epithelial cell migration by targeting RhoGAP activity to 
cell-cell junctions (Omelchenko and Hall, 2012). Staining for paxillin showed 
that even though the cells have a different shape and actin organisation, 
numbers of focal adhesions remain comparable between controls (Figure 
5.8C) and cells after Myo9a knockdown (Figure 5.8D). 
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Figure 5.8 Effect of Myo9a knockdown on morphology of BPH-1 cells. 
A, B. Images of control (A) and Myo9a knockdown (B) BPH-1 cells stained 
for F-actin using fluorescent phalloidin to show their morphology. The 
fluorescent images are shown in reverse contrast for increased clarity. Scale 
bar = 30 μm. C, D. Images of control (C) and Myo9a knockdown (D) cells 
stained for F-actin (AF546-phalloidin – red), paxillin (green) and nuclei (DAPI 
– blue). Arrows indicate large focal adhesions, present both in control and in 
the knockdown cells. Control cells were treated with non-targeting siRNA 
(NT). Scale bar = 30 μm. The images are representative of at least 3 
separate experiments. 
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5.2.5  Myo10 is highly expressed in glioblastoma cell lines 
Next, I investigated if Myo1b, Myo10 and Myo18a were upregulated in a 
brain cancer cell line, glioblastoma. Immunoblotting showed that among the 
three myosin isoforms upregulated in prostate cancer, only Myo10 was 
expressed at high levels in glioblastoma cell line (Figure 5.9A and B). I 
compared levels of Myo10 in prostate cancer cell lines and two glioblastoma 
cell lines: glioma p53-/-PTEN-/- and glioma PTEN-/- (Figure 5.9B). So called 
“headless” Myo10 (Hdl-Myo10) isoform is expressed in the nervous system 
(Sousa et al., 2006). Hdl-Myo10 lacks a functional motor domain, has a 
molecular weight of 164 kDa, and it was recognised by the antibody in 
glioblastoma cell lines but not in prostate cancer (Figure 5.9B), in agreement 
with this isoform’s expression pattern (Sousa et al., 2006). Interestingly, 
glioma p53-/-PTEN-/- showed higher levels of Myo10 than glioma PTEN-/-, 
while glioma PTEN-/- showed noticeably higher levels of Hdl-Myo10 in 
comparison to glioma p53-/-PTEN-/- (Figure 5.9B). When stained for Myo10 
and actin, glioblastoma p53-/-PTEN-/- cells showed Myo10 localised at the 
end of their multiple actin-rich protrusions (Figure 5.9D). The glioma PTEN-/- 
cells also showed protrusions although longer and more sparse (Figure 
5.9C). Both cell lines grow as a connected network. 
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Figure 5.9 Myosins in p53-/-PTEN-/- glioblastoma. A. Immunoblotting 
shows levels of Myo1b, Myo10 and Myo18a in the glioblastoma cell line. 
GAPDH used as loading control. B. glioblastoma cells stained for actin 
(AF546-phalloidin – red)  and Myo10 (green). Arrow shows Myo10 punctae 
concentrated at the tips of protrusions. Scale bar = 30 m. The images are 
representative of at least 3 separate experiments. 
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5.2.6  Knockdown of Myo10 in p53-/-PTEN-/- glioblastoma reduces 
the number of protrusions and affects focal adhesions. 
As Myo10, but not Myo1b or Myo18a, was expressed at relatively high 
levels, I used siRNA to deplete Myo10 expression only, in the glioblastoma 
cell line (Figure 5.10A), and examined the effects on the protrusions. 
Staining for F-actin showed that the shape of Myo10-depleted cells was 
altered, numbers of stress fibres increased, and the cell area was also 
slightly increased (Figure 5.10B, quantified in Figure 5.10C). Interestingly, 
knockdown of Myo10 in glioblastoma decreased the number of protrusions 
per cell (Figure 5.10B, quantified in Figure 5.10D), similarly to the phenotype 
changes seen in PC3 cells. 
Staining of glioblastoma cells for actin and paxillin revealed that Myo10 
depletion additionally affected focal adhesions in glioblastoma cells. Control 
cells show some focal adhesions at the tips of protrusions (Figure 5.11A). In 
contrast, after Myo10 knockdown, prominent actin stress fibres appeared in 
the large cells, with large, well-developed focal adhesions at their ends, 
suggesting a more adhesive phenotype (Figure 5.11B, arrows). These 
results suggest that the role of Myo10 in cell migration might be widespread 
among other types of cancer.  
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Figure 5.10 Knockdown of Myo10 affects morphology of p53-/-PTEN-/- 
glioblastoma. A. Immunoblotting confirms that knockdown of Myo10 in  
p53-/-PTEN-/- glioblastoma cell line using murine siGENOME SMARTpool 
siRNA for 72 hours noticeably reduced Myo10 protein level. Control cells 
were treated with non-targeting siRNA (NT). Molecular markers are shown to 
the right. GAPDH was used as loading control. B. Images of control (NT) 
and Myo10-depleted glioblastoma cells stained for F-actin using fluorescent 
phalloidin to show changes in morphology. The fluorescent images are 
shown in reverse contrast for increased clarity. Scale bar = 30 m.  
The images are representative of at least 3 separate experiments.  
C, D. Quantification of filopodial number (C) and cell area (D). Bars show 
mean + SD for n=20 cells from at least 3 separate experiments. Statistical 
analysis was performed using two-way ANOVA. Levels of significance 
indicated by: (***) for p<0.001.   
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Figure 5.11 Knockdown of Myo10 affects focal adhesions of  
p53-/-PTEN-/- glioblastoma. Control (A) and Myo10 knockdown (B) 
glioblastoma cells stained for F-actin (AF546 phalloidin, red) and paxillin 
(green). Arrows indicate large focal adhesions in knockdown cells. Control 
cells were treated with non-targeting siRNA (NT). Scale bar = 30 m The 
images are representative of at least 3 separate experiments.  
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5.3 Discussion 
The results presented here show that myosins are expressed and can be 
important in benign prostate tissue and glioblastoma. BPH-1, a benign 
prostatic hyperplasia cell line, shows high endogenous expression levels of 
some myosins when compared to prostate cancer cell lines. Levels of 
Myo1b are 1.5-fold higher than in PC3 cells, with Myo1b localising to 
membrane ruffles and actin-rich area between neighbouring cells. Levels of 
Myo10 are 2-fold lower in BPH-1 than in PC3 cells, and this number is 
reflected in numbers of filopodia: BPH-1 have on average half the number of 
filopodia seen in the PC3 cell line. High endogenous expression levels of 
Myo10 in another type of cancer, glioblastoma, are also associated with high 
numbers of protrusions. Knockdown of Myo10 in glioblastoma significantly 
decreases the numbers of filopodia, increases the cell area and affects focal 
adhesions. These changes are analogous to those observed in PC3 cells in 
Chapter 4 and suggest a broader role for Myo10 in cancer motility. 
 
5.3.1 Benign prostatic hyperplasia 
The BPH-1 cell line retains many characteristics of a benign prostate 
epithelium in terms of its morphology, enzymatic activity and testosterone 
metabolism (Hayward et al., 1995). However, one has to remember that this 
cell line is delivered from hyperplastic tissue, which means differences to 
normal prostate epithelium could be present. Other differences could occur 
because of the way the cell line has been established. For example, the 
primary cultures from which the cell line was derived showed very low levels 
of p53 (below detection level by immunofluorescence and western blotting), 
while BPH-1 cells show strong nuclear staining for p53 (Hayward et al., 
1995). This upregulation and stabilisation of p53 is typical for SV40-
immortalised cell lines – the SV40 large T antigen makes the p53 protein 
dysfunctional, as a result of sequestration to oncogene products (Ludlow, 
1993), and it cannot be excluded that this changes the cell line behaviour. 
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The cell line shows no tumorigenic or metastatic potential when injected into 
nude mice (Hayward et al., 1995).  
An unexpected observation in the BPH-1 cell line was the high level of 
expression of Myo1b, which was higher than in previously analysed in 
benign tissue (as shown in chapter 3: GEO analysis, Figure 3.1, and in 1535 
NP, Figure 3.3 and 3.4). One could speculate that high proliferation of 
hyperplastic tissue requires intensive endocytosis, hence elevated 
expression of endocytosis-related proteins such as Myo1b. Since Myo1b 
was present in filopodia or tunnelling nanotubes in PC3 cells, it would be 
interesting to check if it plays a role in cell-cell transport, especially that in 
BPH-1 cells in localises particularly on the borders between cells. The BPH-
1 cell line also showed relatively high numbers of filopodia (comparable to 
DU145 cells and 2-fold lower than in PC3 cells), which I did not expect to 
see in a cell line which has no metastatic potential. 
On the other hand, knockdown of Myo1b or Myo10 did not result in large 
changes in the BPH-1 cells. The focal adhesion status remained unchanged, 
and although Myo10-depleted cells seemed to have increased cell area and 
decreased number of filopodia (by ~30%), the changes were not nearly as 
drastic as in the malignant PC3 cells. Together, these results suggest that 
Myo1b and Myo10 might play a different, possibly more important roles in 
cancer cells than benign prostate cells, making them good potential 
candidates for therapeutic targets. Further study of the myosin knockdown 
seems necessary to check whether other processes such as endocytosis 
are affected. On the other hand, after knockdown of Myo18a I observed 
increased formation of NM2A filaments, suggesting that Myo18a is still 
important for NM2A organisation in benign prostate cells. 
In contrast to the myosin isoforms upregulated in prostate cancer, Myo9a 
seems to be important in BPH-1, particularly for cell-cell adhesion as 
previously shown in 16-HBE (human bronchial epithelium) cells 
(Omelchenko and Hall, 2012). Knockdown of Myo9a in 16-HBE cells caused 
increased scattering of epithelial cells, similar to what I observed in the  
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BPH-1 cell line, confirming that Myo9a is important for delivering RhoGAP 
activity to cell-cell junctions (Omelchenko and Hall, 2012). It would be 
interesting to check the effects of Myo9b knockdown on BPH-1 cells, but due 
to time restrictions this analysis was not performed. 
 
5.3.2 Glioblastoma and its migration 
Myo10 has been reported to be expressed in high levels in normal brain 
tissue (Berg and Cheney, 2002). Myo10 in neurons has been shown to 
regulate axonal pathfinding, outgrowth of neurites (neuronal projections, 
axons and dendrites) and related processes (Ju et al., 2014; Zhu et al., 
2007). A Myo10 isoform expressed in the nervous system, “headless” 
Myo10 (Hdl-Myo10), which lacks a functional motor domain, has a role in 
dendritic spine development and in axon outgrowth (Sousa et al., 2006), 
where it has been reported to act as a dominant-negative regulator of full 
length Myo10 (Raines et al., 2012). A consequent study showed that the 
Hdl-Myo10 isoform could also serve as a scaffolding protein and increase 
retention of actin-remodelling protein VASP (vasodilator-stimulated 
phosphoprotein) in dendritic filopodia to promote their maturation into 
dendritic spines (Lin et al., 2013). In the glioma cell lines, I also observed the 
Hdl-Myo10 isoform, with higher levels in glioma PTEN-/- than in glioma p53-/-
PTEN-/-, which could explain why PTEN-/- cells showed longer and less 
frequent, more “mature” protrusions than p53-/-PTEN-/- glioma cells. 
The role of myosins in glial cells has been less well studied, and has been 
focused around the study of malignant gliomas (incl. glioblastomas), primary 
brain tumours that often have poor prognosis (Buckner et al., 2007; Stupp et 
al., 2007). High mortality rates observed in these tumours can be contributed 
to the fact that although they rarely spread outside of the CNS, gliomas are 
able to invade within the brain very efficiently (Lim et al., 2007; Thorne and 
Nicholson, 2006). When gliomas invade the brain they typically migrate 
through white matter and infiltrate cortical and subcortical grey matter 
structures. For this process, but not for 2D migration, glioma cells have been 
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shown to require myosin 2 (Beadle et al., 2008; Gillespie et al., 2001). When 
carcinoma cells invade the brain, they do not infiltrate it but grow as a 
constrained, expansive mass (Beadle et al., 2008). This would suggest that 
gliomas use a different migration mechanism to carcinomas. The authors of 
this study claim the difference stems from the fact that carcinoma cells 
require formation of a broad lamellipodium to migrate and this is impossible 
in the restricted environment of the brain (Beadle et al., 2008). This 
argument does not seem convincing, since formation of a lamellipodium is 
mostly seen in migration on 2D, flat surfaces (Friedl and Wolf, 2003). Even 
glioma cells, when plated on a coverslip, form a broad lamellipodium and 
migrate much like epithelial cells, as reported by the same study (Beadle et 
al., 2008). In 2D environment, human and rat glioma cells migrate into a cell 
free zone with a velocity of 0.13 and 0.19 m/min, a speed that is 
considerably lower than that observed for PC3 cells (Chapter 4, Figure 
4.10), and although the authors also show much higher velocity of 0.5 
m/min for control glioma cells in a separate figure, this discrepancy is never 
explained. I was unable to observe motility for p53-/-PTEN-/- glioblastoma 
cells despite several attempts. This could be due to cell line-specific 
differences or differences in experimental conditions: for example, the study 
describes glioma cells grown to confluence and migrating in a scratch assay, 
while in my knockdown experiments the cells were grown to 30-40% 
confluence.  
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Chapter 6. Discussion 
 
I have presented a novel study that has investigated expression and 
potential roles of myosins in metastatic prostate cancer. The data show that 
a subset of myosins, including Myo1b, Myo9b and Myo10, is upregulated in 
localised and metastatic tumours. Myo1b, Myo9b, Myo10 and Myo18a 
contribute to the morphology and migration of a highly metastatic PC3 cell 
line. Myo10 promotes filopodia formation and has an evident contribution to 
cell migration, not only in prostate cancer but also in other types of cancer, 
including the highly invasive glioblastoma. High levels of Myo9b are linked to 
low levels of stress fibres. Myo1b and Myo18a influence cell morphology and 
actin organization, but have little effect on migration in 2D, while all 4 
isoforms inhibit cell migration of PC3 cells in 3D invasion assays. Thus, 
changes in expression of several myosin isoforms may contribute to 
metastasis in prostate cancer, and myosins could potentially serve as 
therapeutic targets or diagnostic markers for metastatic disease. 
Of all the myosins screened in this study, Myo10 emerges as possibly the 
most important isoform for migration of prostate cancer cells. Levels of 
Myo10 expression clearly correlated with numbers of filopodia in the different 
cell types that I investigated. There was also an evident link between Myo10 
and cell migration and invasion. While filopodia are not necessarily essential 
for migration, high levels of Myo10 increase their numbers, and enhance 
migration and invasion of cancers. In breast cancer, high levels of Myo10 
were shown to be important in transporting integrins to the filopodial tips for 
invasion (Arjonen et al., 2014).  Thus our finding appears to broadly agree 
with the reports that Myo10 overexpression leads to metastasis in breast 
and lung cancer (Arjonen et al., 2014; Cao et al., 2014; Sun et al., 2015). 
The breast cancer study also showed that mutant, but not wild type p53 was 
important for upregulating Myo10 expression levels through upregulation of 
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the MAPK/ERK pathway and increased levels of EGR1 transcription factor 
(Arjonen et al., 2014). Mutant p53 has been shown previously to drive 
random cell motility and increase invasiveness through enhancing recycling 
pathways of β1 integrins (Muller et al., 2009). Mutations of the TP53 tumour 
suppressor gene are one of the most common among cancers and mutant 
p53 promotes cell migration and metastasis (Oren and Rotter, 2010). In 
many types of human cancers, overexpression of mutant p53 is associated 
with a poor prognosis, consistent with the idea of a “gain of function” 
mutation, in contrast to loss of expression of WT p53 seen in other cancers 
(Selivanova and Ivaska, 2009). However, while p53 has a central role in 
preventing cancer in humans (Lane and Levine, 2010), we still do not fully 
understand how it functions.  
In contrast to the breast cancer study, PC3 cells express high levels of 
Myo10, which are linked to numerous filopodia, high motility and 
invasiveness, even though they do not express mutant or wild type p53. 
Similarly, there are high levels of Myo10 in the p53-/-PTEN-/- glioblastoma cell 
line, higher than in the PTEN-/- glioblastoma cells. In addition, an in silico 
analysis of the GEO cohort, previously used to examine myosin expression 
showed a significant drop of p53 levels in the metastatic tumours (Chapter 3, 
Figure 3.2). Loss of p53 alone may promote tumour initiation in some 
tissues, tumour progression in others, and in prostate cancer it is 
preferentially selected for in advanced prostate cancer, where it accelerates 
the progression of tumours (Chen et al., 2005). Thus, there must be a 
different mechanism by which levels of Myo10 are upregulated in those 
cells, which is p53-independent. This suggests that the described connection 
of Myo10 with p53 (Arjonen et al., 2014) is cancer type-specific or cell type-
specific. 
Previous reports have linked expression levels of other myosins to the p53 
status of cells. For example, expression levels of Myo6 were shown to be 
upregulated by p53 (mRNA and protein) in some tumour cell lines such as 
H1299, RKO, and LS174T (Jung et al., 2006), through binding of p53 to the 
promoter of the MYO6 gene. However, in MCF7 cells, increasing p53 
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expression levels reduced Myo6 levels (Cho and Chen, 2010). In MCF7 and 
LNCaP cells, DNA damage increased expression of p53 and decreased 
Myo6 expression. We found that levels of Myo6 are high in LNCaP cells, 
which do express wt p53 and low in PC3 cells, which do not, suggesting that 
p53 may be regulating Myo6 expression levels in these cell types. However, 
these trends can also depend on the way the cell lines have initially been 
established (transformation method), or be more complex since p53 is 
involved in multiple cell signalling events (Cho and Chen, 2010). 
RNAi mediated knockdown of NM2A predisposes mice to squamous cell 
carcinomas (SCC) (Schramek et al., 2014). This was shown to be related 
not only to actin-related processes, as in epithelial cells where NM2A is 
important for cell-cell adhesion, but was additionally linked to stabilisation of 
p53. In that study, knockdown of NM2A exacerbated SCC formation in mice 
in which TβRII (TGFβ receptor II), but had no effect in mice expressing 
mutant p53 in the skin epithelium. Knocking down NM2A function with 
blebbistatin prevented p53 accumulation in the nucleus.  
Our results suggest that each myosin has a specific effect on actin 
organisation, and increasing their expression in cells with metastatic 
potential may allow them to work in concert to generate a torpedo-shaped 
cell with multiple protrusions that is better able to migrate through a 3D 
matrix and thus more able to metastasise in vitro. Alternative explanation to 
some of the changes observed after myosin knockdown could be that they 
are a secondary consequence of myosin loss. For example, changes to 
integrin transport after Myo10 knockdown could cause disrupted signalling 
and thus indirectly result changes in the actin organisation. Further studies 
will be necessary to rule out the unspecific results and discover the exact 
mechanisms behind the observed changes. What is more, how cancer cells 
move depends on their environment, and this is true in case of malignant 
gliomas (Beadle et al., 2008; Wong et al., 2015) but also for other types of 
cancer. It would therefore be interesting to study the role of myosins in 
assays that better reflect the 3D environment in vivo, for example looking at 
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glioma cell motility in an conditions similar to the particular extracellular 
environment found in the brain. 
Several strategies could be used to utilise the role of myosins in therapy. 
One approach, for example, could be to target particular myosins, for 
example using small-molecule inhibitors. Small molecule myosin inhibitors, if 
selective and sufficiently potent, could be a useful resource for developing 
treatments for diseases involving myosin dysfunction or overactivity. So far, 
small-molecule inhibitors have been developed for myosins in class 2 
(muscle and non-muscle) and classes: 1, 5 and 6 (Bond et al 2013). Most of 
the inhibitors operate by hindering ADP/Pi release by the myosin ATPase 
(Bond et al., 2013). Blebbistatin, the most well-known inhibitor, specific to 
non-muscle myosin 2, has been shown to inhibit migration, invasion and 
spreading of cancerous cells such as pancreatic adenocarcinoma and breast 
cancer in culture (Derycke et al., 2011; Duxbury et al., 2004). Despite efforts 
in the scientific field, there are not that many inhibitors and none of them 
have been applied or tested in therapeutic aspects. Limitations when using 
inhibitors include lack of specificity as well as the range of concentrations at 
which the compound would have to be available in the patient to work 
efficiently. 
Additionally, small-molecule myosin inhibitors can serve as a useful tool for 
understanding myosin function. An interesting addition to the field would also 
be a complementary design of small-molecule myosin activators. Specific 
myosin inhibitors (and even activators) could provide valuable, 
complementary experiments to this study. One can imagine analysis of 
certain myosins, such as Myo10 and/or Myo9b, activated in the LNCaP cell 
line, effect of Myo6 activation in the PC3 cell line, or an experiment where 
several myosins could be inhibited in the PC3 cells at once. This approach 
could also be studied using established cell lines missing or overexpressing 
certain myosin isoforms, although the inhibitors offer an advantage of time- 
efficiency. 
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Rather than looking at particular molecules, a different tactic in cancer 
therapy is to take a broader, “blanket” approach. Although cancers are a 
group of diverse diseases, they can often be summarised by categories of 
dysfunctions such as the “hallmarks of cancer” (Hanahan and Weinberg, 
2000). Besides, as shown by the example of Myo18a and NM2A, myosins 
can work together and they often have overlapping functions. This general 
approach can target proteins involved in regulatory processes or in cell 
migration, especially when targeting metastatic cancer. One example of a 
therapy that targets a cytoskeletal protein are the taxanes, such as 
docetaxel, which inhibit polymerisation of tubulin (Dreicer, 2006). Taxane-
based chemotherapy is one of the few therapeutic options that have proven 
to be somewhat effective in metastatic castration-resistant prostate cancer, 
although for a very limited period of time (Dreicer, 2006). In general, 
prostatic adenocarcinoma tumours respond poorly to standard 
chemotherapeutic intervention (Augello et al., 2014; Berthold et al., 2005; 
Dreicer, 2006).  
Another common strategy general across various types of cancer includes 
Heat shock protein 90 (Hsp90) as a potential therapeutic target. Hsp90 is an 
evolutionary conserved molecular chaperone that stabilises and activates 
many proteins essential for cell signalling and adaptive responses to stress 
(Zhao et al., 2005). Cancer cells can use the Hsp90 chaperone to protect 
mutated or overexpressed oncoproteins from misfolding and degradation, 
and it is often recognised as a crucial facilitator of cancer cell survival 
(Trepel et al., 2010). Hsp90 is therefore often upregulated in advanced 
cancers, and I have also observed this to be the case in the in silico analysis 
of the GEO profiles for prostate cancer (Figure 3.2).  
Considerable progress has been made in the field of Hsp90 inhibitors, and 
even though none of them are approved, a number of inhibitors are currently 
undergoing clinical evaluation in cancer patients (Jhaveri and Modi, 2015; 
Trepel et al., 2010). Therapy can also target Hsp90 clients, such as protein 
kinases, involved in the proliferation and survival of cancer cells, which 
depend on chaperone activity of Hsp90 (Miyata et al., 2013). One example is 
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cell surface receptor tyrosine kinases, such as ErbB2/HER2 overexpressed 
in breast cancer which are targeted by Trastuzumab (Herceptin), monoclonal 
antibody drug which binds to ErbB2/HER2 and prevents the ErbB2/HER2-
dependent progression of metastatic breast cancer (Sachdev and Jahanzeb, 
2012). In prostate cancer, however, it seems that the tumour 
microenvironment and target complexity may complicate clinical efficacy. 
Initial preclinical observations suggested that castrate-resistant prostate 
cancer might respond well to IPI-504 (retaspimycin), a Hsp90 inhibitor 
therapy, since Hsp90 regulates the activity of androgen receptor (AR) 
(Saporita et al., 2007). However, the inhibitor was not effective in 
monotherapy of castration-resistant prostate cancer (Oh et al., 2011). This is 
similar to what has been reported for an analogous inhibitor, 17-AAG (Heath 
et al., 2008). These results could be explained by a study which showed that 
inhibition of Hsp90 by 17-AAG activates osteoclast Src kinase and promotes 
Src-dependent osteoclast maturation, and as a consequence, instead of 
acting against prostate cancer growth, Hsp90 inhibitor stimulates the growth 
of prostate carcinoma cells in the bone (Yano et al., 2008). By contrast, 
more promising results have been reported for multiple myeloma and for 
subtypes of breast cancer (Augello et al., 2014). These differences 
emphasise the value of choosing a cancer that is driven by an Hsp90 “client” 
protein (such as HER2 in breast cancer), as well as the importance of 
possible long-term impact of Hsp90 inhibitors on normal tissues (Augello et 
al., 2014; Yano et al., 2008).  
Apart from the general chaperones, another protein that could potentially be 
targeted in therapy is myosin chaperone, UNC-45A. UNC-45A is an isoform 
of UNC-45 expressed in non-muscle cells, specific to non-muscle myosins, 
while UNC-45B is a chaperone specific to muscle (Price et al., 2002). 
Elevated levels of UNC-45A have been found in ovarian tumours, with 
higher levels exhibited by metastatic tumours (Bazzaro et al., 2007). Another 
study showed that not only is UNC-45A accumulation increased in breast 
carcinoma specimens and cell lines, but also its knockdown in cell lines 
decreases proliferation and invasion rates (Guo et al., 2011). UNC-45A also 
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co-localises with NM2A in the centrosome and regulates proliferation of 
HeLa cells (Jilani et al., 2015). However, my in silico analysis showed that 
UNC-45A was significantly decreased in metastatic prostate cancer and no 
reports exist on the role of myosin chaperones in prostate cancer. Future 
study of the regulatory mechanisms of UNC-45A expression and biological 
action could improve its potential function in prostate cancer. 
Despite advances in early diagnosis, surgical techniques, systemic 
therapies, and patient care, modern anticancer therapy is still challenged 
greatly by metastatic dissemination. Metastasis frequently occurs prior to 
diagnosis of a primary tumour, which is why surgical excision is not curative. 
Continual empiricism in the treatment of cancer also seems unlikely to 
produce significant improvements and therefore understanding the 
mechanisms responsible for cancer metastasis should be a primary goal of 
research (Fidler, 2011). Indeed, incredible recent progress has been 
achieved in the field and new knowledge has been gained of the 
pathogenesis of metastasis on the systemic, cellular and molecular levels. 
Multiple other approaches and strategies are being taken on by researchers 
in the fight against cancer metastasis. In case of prostate cancer, targeting 
the androgen receptor or subpopulations of cancer stem-like cells 
(Bhattacharya et al., 2015; Frame et al., 2013). More generally, it could also 
mean targeting stroma interaction and tumour-associated cells (Calvo and 
Sahai, 2011), inhibiting various molecules in signalling pathways involved in 
regulation of cell migration (Hotary et al., 2003; Vega et al., 2012; Wellbrock 
and Hurlstone, 2010), looking at aneuploidy or chromatin regulations 
(Donnelly et al., 2014; Zhu et al., 2015). To date, however, many of these 
approaches render inefficient.  
This is partly because, depending on their molecular repertoire, tumour cells 
possess notable plasticity to change between different invasion modes and 
adjust migration mechanisms to cope with therapeutic challenge (Friedl and 
Wolf, 2003). The spectrum of adaptation responses observed for invasive 
migration implicates diverse mechanical and signalling programs in cancer 
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cell migration that adapt to molecular challenge during disease progression 
and, possibly, during therapeutic challenge (Alexander and Friedl, 2012). 
This means that there is still an urgent need to improve our understanding of 
cancer metastasis. We believe myosins might be an attractive object of 
study in this context, because of their ubiquity and multiple specific 
functions, some possibly dysregulated in cancer. This might present an 
opportunity for myosins to serve as ‘crucial points’ of the network of 
interactions involved in metastasis. An ideal therapy would not leave the 
cancerous cell an option to omit the challenge, but compensatory changes 
negating the effect would be available in normal cells. This is why it would be 
interesting to expand this study to check whether the analysed subset of 
myosins could be potential targets for therapy in other types of cancer or 
more specifically in prostate cancer.  
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